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ABSTRACT  
 
Cardiovascular effects of (13S)-9α, 13α-epoxylabda-6β(19), 15(14)diol dilactone, a  
diterpenoid isolated from the organic extract of Leonotis leonurus leaves,  in 
anaesthetized normotensive rats” 
 
K. C. Obikeze  
 
Plants used in traditional medicines have served as sources of some of the drug compounds 
used in medicines today, and could still serve as leads for the development of new drugs to 
treat existing chronic diseases such as hypertension. This study was aimed at the isolation 
and identification of a cardio-active compound from L. leonurus, a plant commonly used in 
traditional medicines in South Africa for the treatment of hypertension and other cardiac 
problems. The possible mechanisms by which the isolated compound produced its effect on 
the cardiovascular system were explored using the anaesthetized normotensive rat model.  
Fractionation of the organic extracts of the leaves led to the isolation of a novel diterpene, 
(13S)-9α, 13α-epoxylabda-6β(19),15(14)diol dilactone (EDD) whose structure was 
elucidated using infra red (IR), nuclear magnetic resonance (NMR), mass spectroscopy 
(MS), and X-ray diffraction analysis. In anaesthetized normotensive male Wistar rats, EDD 
(0.5 mg/kg – 5.0 mg/kg; IV) produced slight non-significant decreases in systolic pressure 
(SP), diastolic pressure (DP), and mean arterial pressure (MAP) with the lower (0.5 mg/kg 
– 2.0 mg/kg) doses, while significant increases in SP, DP and MAP occurred with the 
higher (3.0 mg/kg – 5.0 mg/kg) doses. All doses of EDD administered also produced 
significant decreases in heart rate (HR).   
Prazosin and reserpine pre-treatment abolished the vasoconstrictive effect of EDD, 
suggesting an indirect vasoconstrictive effect for EDD via the release of catecholamines. 
 
 
 
 
Atenolol pre-treatment led to increases in the negative chronotropic effect of EDD, while 
the positive chronotropic effect of dobutamine was significantly decreased by EDD, 
suggesting the involvement of the β1 adrenoceptor in the negative chronotropic effect of 
EDD. In animals pre-treated with verapamil, a cardio-selective Ca2+ channel blocker, no 
significant changes in HR occurred with all EDD doses, but HR values were significantly 
lower than those obtained with EDD in non pre-treated animals. 
The results of this study indicate that (13S)-9α, 13α-epoxylabda-6β(19),15(14)diol 
dilactone, a novel dilactone diterpene isolated from the leaves of L. leonurus has an effect 
on the cardiovascular system. EDD exhibits a dual effect on the cardiovascular system by 
producing a vasoconstrictive effect accompanied by bradycardia. The vasoconstrictive 
effect of EDD is probably due to the release of catecholamines, while the negative 
chronotropic effect is probably due to β1 adrenoceptor antagonism. Further studies are 
however required to fully determine the mechanism by which EDD produces its 
cardiovascular effects. 
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CHAPTER ONE 
Introduction 
There is no generally accepted date as to when man first began using plants as a source of 
medicine, but it is well accepted that plants have for a long time played a dual role as food 
and medicine. Early practitioners probably observed by trial and error or by pure accident 
the beneficial and harmful properties of certain plants and this may have sparked an interest 
in the medicinal properties of plants that endures to this day. Evidence of the extensive use 
of plants as drugs can be found in ancient literature originating from China, India, and even 
in Egyptian hieroglyphics (Farnsworth, 1990; Pemberton, 1999; Mahady, 2002; 
Patwardhan, 2005). Since most ancient African societies had no written language, 
important traditional medicinal recipes were preserved in oral traditions and examples 
abound in the folklore of all African societies (Williamson et al., 1996). The use of plants 
as medicines has remained through the ages, especially in traditional societies in Africa, 
South America and Asia where traditional medicine remains an integral part of their 
culture. 
 
Traditional medicinal practices evolved from the fusion of cultural practices with the use of 
plants, minerals and animals as medicines, and can be defined as the totality of knowledge 
and practices that are based on an indigenous belief system, which are used for the 
maintenance of health and the prevention or complete elimination of physical and/or 
mental disorders (Tabuti et al., 2003). Early medications started out as decoctions, 
poultices, ointments, or solutions of plants, animal parts and minerals. Twentieth century 
advances in medicine such as the discovery of penicillin and morphine led to the decline of 
 
 
 
 
the use of traditional medicines and the disappearance of many of the traditional 
indigenous medicinal practices. As a consequence a great number of these remedies have 
disappeared with time, although some still presently find use for the treatment of diseases 
by traditional medicine practitioners of all cultures. In present times, despite the abundance 
of synthetic and semi-synthetic drugs, a significant proportion of the population of 
developing countries still depend on traditional medicines for their health care needs. The 
World Health Organization (WHO) estimates that 60% of the world’s population is 
dependent on traditional medicines for their primary health care needs, with the figure 
rising to about 80% of the population in developing countries (Farnsworth, 1990; Zhang, 
2000; Mulholland, 2005). Interestingly about 15-20 million of the traditional medicine 
users in developing countries reside in Southern Africa alone (Duncan et al., 1999). South 
Africa is a country with a large biodiversity of over 30 000 higher plant species of which 
approximately 3000 are presently used as medicines by an estimated 27 million people 
(Mander et al., 1997). In addition to this, it is estimated that 80% of the population consult 
traditional healers first for their health problems (Duke, 2001). It is therefore no surprise 
that as of 1996, an estimated 20 000 tonnes of over 700 medicinal plant species were traded 
yearly in South Africa (Mander et al., 1997). In recent times, the persistence of chronic 
diseases such as asthma, heart diseases, and diabetes, the rising HIV epidemic, coupled 
with the rising cost of medicines has led to a renewed interest in the use of traditional 
medicines in societies where traditionally they were used and also in western countries that 
had previously seen little demand for traditional medicines.  
 
 
 
 
 
In recent years, an increase in the prevalence of ‘diseases of lifestyle’ such as diabetes and 
cardiovascular disorders has been noted in developing countries (Reddy et al., 2006). With 
respect to cardiovascular diseases, these changes have led to an increased disease burden 
on public health facilities as well as an increase in mortality and morbidity (Tabuti et al., 
2003). Though there are many medicines in use for the management and treatment of these 
diseases, the search for better treatment regimes for hypertension and other cardiovascular 
diseases continues. In developing countries a large number of the individuals suffering 
from these diseases are not able to afford the existing medicines and so depend on cheap 
and readily available traditional medicines for treatment or cure. With the recent increase in 
research interest in traditional medicines, a lot of the research into traditional medicine has 
been focused on their use in the treatment of cardiovascular diseases. A large number of the 
plants used in traditional medicines are claimed to be effective in treating ‘heart problems’, 
though some claims are more specific for cardiovascular conditions such as congestive 
heart failure (CHF), systolic hypertension, angina pectoris, arteriosclerosis, cerebrovascular 
insufficiency, venous insufficiency and cardiac arrhythmias (Mashour et al., 1998; van 
Wyk et al., 2000).Various researchers have documented the extensive use of plants as 
diuretics, cardiotonics, antihemorrhagics, antioxidants, and as vasodilators in the treatment 
of cardiovascular diseases (van Wyk et al., 2000). Examples of such plants include Ginko 
biloba for the treatment of heart diseases, Stephania tetandra for the treatment of 
hypertension, Lingusticum walliichii as a circulatory stimulant and an antihypertensive 
drug, and Uncaria rhynchophylla for hypertension (Mashour et al., 1998; Mahady, 2002). 
In South Africa Leonotis leonurus has been used extensively in traditional medicine for the 
treatment of cardiovascular diseases (van Wyk et al., 2000). 
 
 
 
 
The use of plant medicines has evolved with time, from the use of simple preparations of 
plant parts, to the use of pure chemical compounds isolated from plants (Noumi et al., 
1999). In the 19th and 20th centuries, the isolation of very important chemicals like 
morphine, quinine, reserpine and penicillin from plants initiated a sustained period of 
bioprospecting, which only gradually declined with the rise of the petrochemical industry 
and the development of synthetic and semi-synthetic drugs (Manitto et al., 1981). Presently 
most of the drugs used in therapy are synthetic in origin, but approximately 25% are or 
were originally derived from plants and are used as either pure chemicals or as they appear 
in nature (decoctions or extracts of leaves, barks, fruits, flowers, and roots) (Kutchan, 
1995). Plants have also served as templates from which synthetic drugs have been 
designed. Tropicamide derived from atropine, an alkaloid obtained from Atropa 
belladonna, chloroquine derived from quinine, procaine and tetracaine derived from 
cocaine obtained from coca leaves are some well known examples. Though the trend of 
drug discovery has shifted further away from plants as more and more drugs are synthetic 
in origin, the therapeutic potential of plants still abounds. A recent resurgence in 
bioprospecting has been fueled by the therapeutic use of plants in situations where 
conventional therapy has had little effect such as the use of Silybum marianum to prevent 
liver damage from the death cap mushroom and infectious hepatitis, the use of immune 
stimulants from coneflower for viral infections, artemisinin from Artemisia annua to treat 
drug-resistant malaria and the controversial use of Cannabis sativa to treat pain and nausea 
in cancer and cancer chemotherapy (Kutchan, 1995). The demand for new drugs for the 
treatment of diseases such as cancer, diabetes, hypertension and AIDS has also contributed 
to the resurgence in research into the pharmacological effects of traditional medicines. 
 
 
 
 
Presently there are about 119 plant-derived chemical compounds of known structure in use 
as drugs. Interestingly only 90 species of the 250 000 species of higher plants on the planet 
contribute to these plant-derived chemical compounds in present use (Cox, 1990). Since 
plants contain a wide variety of complex organic molecules, they are presently the target of 
many researchers looking for new bioactive molecules or molecules to serve as lead 
compounds in pharmaceutical drug design (Rates, 2001).  
 
The WHO has long encouraged the promotion and development of traditional medicines, 
especially in developing countries where there has been a sustained practice of traditional 
medicines (WHO, 2002). South Africa has been one of the countries on the forefront of this 
move as evidenced in recent moves to incorporate traditional medicines into the healthcare 
system (Department of Health, 2008). In addition to this, a driving force to the resurgence 
of traditional medicine has been the move by many nations to protect and preserve 
indigenous knowledge systems and floral biodiversity. In South Africa, the government has 
promoted research into traditional medicines, both to preserve indigenous knowledge and 
the essential validation for their use (Department of Health, 2008). Furthermore the 
increase in the concurrent use of traditional and orthodox medicines has increased the need 
for information on traditional medicinal plants in order to accurately predict potentially 
harmful interactions (Rates, 2001). The increase in reliance on traditional medicines, the 
rejuvenation of interest in plant medicines as a potent source of new drugs for chronic 
diseases and the need for a pharmacologic profile of plants in use as traditional medicines 
have lead to a recent increase in research into the pharmacologic effects of plants that are 
used in traditional medicine. With only about 350 of the commonly used and traded plant 
 
 
 
 
species having undergone chemical investigations, there is still a large pool of plant based 
chemicals that could potentially deliver the next major new drug (Soejarto, 1996; Mander 
et al., 1997). This study focused on L. leonurus, a plant widely used in traditional medicine 
in South Africa to treat cardiovascular diseases.  
 
The second chapter of this thesis gives an ethnobotanical description of Leonotis leonurus. 
It also examines the various studies on the composition, pharmacologic and in particular, 
cardiovascular effects of extracts or compounds isolated from the plant. It also describes 
various methods used in the extraction and characterization of compounds from plants. The 
various methods used in cardiovascular research are examined and reasons for choosing the 
method used in the study are given. Finally the motivation for the study, the hypothesis and 
the objectives of the study are stated. Chapter three lists the materials and describes the 
methods used in the study. The methods used in the extraction and characterization of the 
isolated compound and the cardiovascular model used to evaluate its effects are described. 
Chapter four contains illustrations and a description of the results obtained. It describes 
results of the extraction process as well as results of nuclear magnetic resonance (NMR) 
and infrared (IR) spectroscopy, X-ray crystallography and mass spectroscopy (MS) 
experiments carried out on the isolated compound. It also contains a description of the 
results obtained with the administration of the isolated compound and other drugs in the 
anaesthetized normotensive rat model. Chapter five contains a discussion of the results 
obtained. It also contains the conclusions derived from the study and recommendations.  
 
 
 
 
 
CHAPTER TWO 
Literature review 
Cardiovascular diseases such as hypertension and congestive heart failure (CHF) place a 
great burden on health services. The possibility of traditional medicines relieving some of 
this burden has fueled investigations to validate the therapeutic or pharmacologic effects of 
plants used in traditional medicines to treat cardiovascular diseases. To evaluate the 
cardiovascular properties of these plants, various methods and pharmacologic models 
designed to mimic the cardiovascular system have been used. The choice of model usually 
depends on the specific cardiovascular property of the plant being studied, as most of the 
plants are described for use for a wide range of cardiovascular diseases ranging from 
hypertension and congestive heart failure to arteriosclerosis and cerebrovascular 
insufficiency (Sofowora, 1982; van Wyk et al., 2000). While some researchers have 
focused on validating the therapeutic claims of the plants by studying them in the form that 
they are used in traditional medicines, others have attempted to isolate the compounds 
responsible for the cardiovascular effects of the plants.  
In this chapter, the different types of plant extracts and compounds that have been shown to 
exhibit cardiovascular effects will be discussed. A description of L. leonurus, the plant that 
is the focus of this study is given, and its traditional use and reports from previous 
investigations on extracts of the plant are discussed. Some of the methods employed in the 
isolation and identification of compounds from plants and some in vivo and in vitro models 
used in the evaluation of cardiovascular activity will also be discussed. Finally, a 
 
 
 
 
description of the cardiovascular system and its regulatory mechanisms as well as the 
mechanisms by which drugs can alter cardiovascular activity are discussed.  
 
2.1 Plant and plant compounds with cardiovascular effects 
All traditional medicines include recipes of aqueous decoctions of various plant parts such 
as the leaves, stems, roots, barks, and fruits, and for this reason most investigations on the 
cardiovascular activity of plants have focused on the aqueous extracts. In studies of the 
cardiovascular properties of the  leaves of Eremophilia alternofilia, a traditional Aboriginal 
medicinal plant, the aqueous extract was reported to mediate an initial, but transient, 
positive inotropic effect followed by an immediate negative inotropic effect accompanied 
by an increase in heart rate and coronary perfusion on isolated rat hearts perfused by 
Langendorff perfusion (Pennacchio et al., 1995). The aqueous extract of the bark of 
Terminalia arjuna produced positive chronotropic and inotropic effects in studies on the 
isolated frog heart, while in anaesthetized dogs the aqueous extract of the dried bulbs of 
Allium sativum produced diuretic and natriuretic effects (Chopra et al., 1958; Pantoja et al., 
1991; Pantoja et al., 1996). Extracts of Agapanthus africanus, Agave Americana, 
Adenopodia spicata, Clausena anisata, Dietes iridioides, Stangeria eriopus and Tulbaghia 
violacea were shown by Duncan and co-workers (1999) to inhibit angiotensin converting 
enzyme (ACE) in assays of plants commonly used in South Africa to treat hypertension. 
Organic extracts of plants have also been studied for cardiovascular effects, with Jager and 
co-workers (1996) reporting cyclooxygenase enzyme inhibition with ethanol extracts of L. 
leonurus.  Cometa and co-workers (2001) reported reversible increases in blood pressure 
with methanolic and butanolic extracts of Curculigo pilosa in anaesthetized normotensive 
 
 
 
 
rats while methanol extracts of the leaves of Brillantaisia nitens exhibited vasorelaxant 
properties in strips of rat aorta (Dimo et al., 2006).  
Pure compounds isolated from plants have also been studied for their cardiovascular 
effects, with the digitalis glycoside digoxin probably the best known example. In one of the 
early experiments to determine the cardiovascular effects of plant compounds, a glycoside 
isolated from the bark of Terminalia arjuna was found to increase the force of contraction 
of the frog heart and also to raise blood pressure (Dwivedi, 2007). Tetrandrine, an alkaloid 
extract of S. tetrandra, was reported to induce and sustain hypotensive effects in rats for 
more than 48 hours, with effects similar to those of verapamil, a calcium ion channel 
antagonist also used in the study (Mashour et al., 1998). The alkaloids harmine, harmaline 
and harmalol, were found to decrease heart rate in normotensive dogs and isolated rat 
hearts, and increased developed pressure, peak aortic flow and myocardial contractile force 
in isolated perfused rat hearts (Aarons et al., 1977). Ulubelen in 2003 reported 
antihypertensive activity with two diterpenoids from Salvia syriaca; ferruginol and 3β-
hydroxystigmast-5-en-7-one. Diterpene kaurenoids isolated from Alepidea amatymbica and 
Xylopia aethiopica were reported to reduce blood pressure and heart rate in anaesthetized 
rats, dilate coronary vessels, and also exhibit a diuretic effect comparable to that of 
hydrochlorothiazide (Somova et al., 2001). The neo-clerodane diterpenoids, (12R)-12-
hydroxycascarillone and 5-hydroxy-cis-dehydrocrotonin isolated from Croton schiedeanus 
were reported to produce a vasorelaxant effect in isolated aorta rings, while trans-
dehydrocrotonin isolated from Croton cajucara induced hypotension and bradycardia in 
anaesthetized normotensive rats (Guerrero et al., 2004; Silva et al., 2005). The literature so 
far indicates that plant extracts and compounds so far investigated mostly exhibit 
 
 
 
 
hypotensive effects either by reducing heart rate or dilating blood vessels or a combination 
of both. This does not indicate that plants cannot exhibit hypertensive effects, but rather is 
an indication that most investigations are guided by the traditional uses of the plants, hence 
the predominance of hypotensive effects. Interestingly some compounds isolated from 
plants have exhibited a dual effect on the cardiovascular system. Labd-8 (17)-en-15-oic 
acid and labdane-302, two terpenes isolated from Xylopia langsdorffianna produced both 
hypotension and tachycardia in anaesthetized normotensive rats (de Oliveira et al., 2006; 
Lahlou et al., 2007). Visnagin, isolated from the fruits of Ammi visnaga, a plant used for 
the treatment of angina pectoris, was found to lower blood pressure without any effect on 
the heart rate in anaesthetized male Wistar rats by Duarte and co-workers (2000). In 
addition to the phytochemical classes such as alkaloids and terpenes mentioned above, 
other phytochemical classes such as glycosides are known to exhibit cardiovascular effects, 
and flavonoids have been documented to either have a direct effect on the cardiovascular 
system, or to be cardio protective through their lipid lowering actions (Dryskog et al., 
2005; Narender et al., 2006).   
 
2.2 Leonotis leonurus 
Leonotis leonurus R. BR (Laminaceae) is one of ten species that derive their genus name - 
leonotis from the Greek words "leon" (a lion) and "otis" (an ear), describing the typical lion 
ear shaped flowers of the plants. The plant is indigenous to the Southern tip of Africa, and 
is usually found at forest margins, on rocky hillsides, riverbanks and in tall grasslands of 
the Eastern Cape, Western Cape, Kwazulu-Natal and Mpumalanga provinces of South 
Africa (Batten, 1986; van Wyk et al., 2000). The plant is a shrub growing between two and 
 
 
 
 
five meters in height. It has a thick wooden base, pale brown branches and long, hairy and 
narrow leaves with serrated upper edges arranged opposite each other on the stems. The 
bright orange flowers are tubular in shape, and are arranged in circles along branch ends, 
and the fruit consists of four little nutlets seated at the base of the calyx tube (Adamson and 
Salter 1950; van Wyk et al., 2000). Locally the plant is known in the various languages as 
wilde dagga (Afrikaans), wild dagga (English), umunyane (Isizulu), lebake (Sotho) and 
umfincafincane (Isixhosa) (Watt and Breyer-Brandwijk 1962; van Wyk et al., 2000). 
 
 
Figure 2.1: Leonotis leonurus R. BR (Laminaceae) 
 
In going with the traditional use of most shrubs, most documented evidence of the use of 
Leonotis leonurus in traditional medicine indicates the use of the leaves, stems, flowers and 
fruits, administered as decoctions, inhalations, infusions, tonics, or poultices depending on 
the illness (Hutchings et al., 1996). In most communities, the plant is used in traditional 
 
 
 
 
medicine for a wide variety of illnesses ranging from minor ailments like bites, stings and 
boils to major conditions like hypertension, tuberculosis, and epilepsy (Hutchings et al., 
1996; Noumi et al., 1999; Duke, 2001; Ososki et al., 2002). In certain communities 
however its use is more specific; for example it is reported to be used for the treatment of 
menstrual disorders in the Dominican Republic, for hypertension by the Bafa in Cameroon, 
as a strong purgative and an enemagogue by the Hottentots of South Africa, and to relieve 
hemorrhoids by the Zulus (Watt and Breyer-Brandwijk 1962). The dried leaves of the plant 
have been reported to possess mild hallucinogenic effects when smoked, and the leaves 
were also smoked to relieve epileptic fits by the Hottentots of South Africa (van Wyk et al., 
2000). 
Phytochemical analysis of the leaves and stems of L. leonurus have shown that the plant 
contains alkaloids, flavonoids, resins, tannins, terpenoids, saponins, and quinines (Watt and 
Breyer-Brandwijk 1962; Laonigro et al., 1979; Bienvenu et al., 2002). Phytochemical 
studies on the plant have led to the isolation of a number of compounds from the stems and 
leaves of the plant. The compounds so far isolated from the plant include leonurine a 
mildly psychoactive alkaloid, marrubin a labdane type lactone that has also been isolated 
from Marrubium vulgare and is thought to be an artifact of premarrubin produced during 
extraction, marloth a dark green resin that is also thought to be responsible for the plant’s 
narcotic properties, leonitin a terpenoid also found in Leonotis ocymifolia, 1,2,3- 
trihydroxy-3,7,11,15-tetramethylhexadecan-1-yl-palmitate, a diterpene ester, two labdane 
terpenoids known as compounds X and Y, and leonurun (figure 2.2) (Kaplan and Rivett 
1968; Rivett 1964; Habtemariam et al., 1994; Hutchings et al., 1996; van Wyk et al., 2000; 
Duke, 2001; McKenzie et al., 2006; Agnihotri et al., 2009). Most of the compounds so far 
 
 
 
 
isolated from the plant have been terpenoids, and the terpenoids so far isolated from L. 
leonurus have closely related structures usually with the differences being the substituent 
on C-20 and stereoisomerism around C-9, C-13 (see figure 2.2). Other compounds 
however, are quite dissimilar in their structures (figure 2.2). It has been noted that the 
Leonotis species is very rich in terpenoids, especially the diterpenoid lactones, and some 
researchers have also noted possible geographical differences in the phytochemical 
constituents of L. leonurus (Laonigro et al., 1979; McKenzie et al., 2006).  
                        
          
 
 
Figure 2.2: Structures of leonurun (1), premarrubiin (2), marrubiin (3), leonitin (4), 
compound X (5), leonurine (6), compound Y (7) and 1,2,3- trihydroxy-3,7,11,15-
tetramethylhexadecan-1-yl-palmitate (8).  
 
 
 
 
Attempts have been made by various researchers to validate the claims made in traditional 
medicine of the therapeutic use of L. leonurus. An aqueous extract of the leaves was tested 
for anticonvulsant properties by Bienvenu and co-workers (2002) and found to be effective 
in protecting mice against seizures induced by pentylenetetrazole, picrotoxin and N-
methyl-DL-aspartic acid. Extracts of the leaves and stems have also shown antibacterial 
activity in vitro (Kamatou et al., 2006). Organic extracts of the leaves were reported by 
Jager and co-workers (1996), investigating the use of the plant traditionally for treating 
headaches and inflammation, to be a good inhibitor of cyclooxegenase (COX) enzyme. 
Various studies have investigated the cardiovascular effects of different extracts of the 
plant with mixed results. Njagi (2001) reported no significant effect on both blood pressure 
and heart rate in anaesthetized normotensive Wistar rats with a 1 mg/ml infusion of the 
aqueous extract, while Ojewole (2003) on the other hand reported decreases in blood 
pressure and heart rate in anaesthetized, normal and spontaneously hypertensive rats. The 
differences may be explained as dose related since Ojewole administered 22 – 800 mg/kg 
doses of the extract, doses far greater than the 1mg/ml dose used by Njagi. In another study 
however Obikeze (2005) administered 0.5 – 7.0 mg/kg of the aqueous extract to 
anaesthetized normotensive rats and observed increases in blood pressure and decreases in 
heart rate, a result strikingly different from that reported by both Njagi and Ojewole. 
Obikeze (2005) also reported an increase in blood pressure and heart rate with a 
chromatographic fraction of the methanol extract of the leaves. In vitro studies on the plant 
also yielded conflicting results, with Mugabo and co-workers (2002) reporting a positive 
chronotropic and inotropic effect on isolated Langendorff perfused male Wistar rat hearts 
with the aqueous extract, while Ojewole (2003) reported the aqueous extract to relax 
 
 
 
 
vascular smooth muscle contractions induced by bath-applied noradrenaline (0.1-10 M), 
and potassium (5- 40 mM) in strips of the descending aorta and portal vein. Despite the 
number of compounds so far isolated from the plant, none have so far been evaluated for 
pharmacologic activity. Though extracts of the plant have been studied for cardiovascular 
activity, a definitive mechanism of action for the cardiovascular effects of the extracts or 
pure compounds so far isolated from the plant is yet to be elucidated. The literature 
revealed that a variety of plant derived compounds exhibit varying effects on the 
cardiovascular system and plants belonging to the Leonotis spp contain a diverse mix of 
these compounds, though especially rich in terpenoids. Since terpenoids have been shown 
to exhibit cardiovascular effects, they could be wholly or partly responsible for the 
cardiovascular effects observed with aqueous and organic extracts of L. leonurus (David et 
al., 1998; Somova et al., 2001; Ulubelen, 2003; Guerrero et al., 2004; Silva et al., 2005; de 
Oliveira et al., 2006; Lahlou et al., 2007). 
 
2.3 Isolation of plant compounds 
Plants contain a mixture of chemical compounds belonging to the different phytochemical 
classes, with different solubility profiles in aqueous and non-aqueous solvents. For the 
isolation of plant compounds, typically the fresh plant is immersed in a suitable solvent and 
the resulting extracts are utilised, but alternatively fresh plant parts could be dried under 
stringent conditions and then extracted with a solvent. Plant parts could also be ground up 
to help break down cells and increase the degree of extraction. Solvent extraction is usually 
the first step in isolating chemical compounds from a plant. Typical solvents used include 
water, ethanol, methanol and hexane, and usually the organic solvents are the more 
 
 
 
 
favoured if an exhaustive extraction is desired. Since plants typically contain a large 
number of chemical compounds, the investigation of plants for possible useful chemical 
compounds usually follows a systematic plan (Harborne, 1973). The classic process is to 
continuously extract the dried and powdered material in a soxhlet apparatus with a range of 
solvents followed by concentration of the resulting extracts. Bioassay guided fractionation 
of the residues of the extracts is usually used when investigators are prospecting for 
compounds that could be useful in specific diseases (Harborne, 1998; Pieters and Vlietinck 
2005). In bioassay guided fractionation, the crude extracts of the plant material are tested 
for the desired biological activity and the active fraction then fractionated.  Fractions 
obtained are evaluated for biological activity and those active fractions are pooled and 
refractionated and retested. This process is repeated until pure compounds with the desired 
bioactivity are finally found (Luo et al., 2008; Ngueyem et al., 2008). Bioassay guided 
fractionation has the advantage of producing pure compounds that have the particular 
desired bioactivity. Investigations are normally focused on a particular disease with the 
idea that compounds isolated could eventually be useful in treating the disease, or serve as 
leads for other useful synthetic compounds. On the downside, the cumbersome cycle of 
fractionation and assaying makes this process time consuming. It has also been noted that a 
lot of the effects of crude plant extracts are the sum of the effects of individual compounds 
found within the extract, and thus a degree of caution must of necessity be adopted in 
bioassay guided fractionation since it may not yield pure compounds with significant 
bioactivity even if the original extracts showed significant activity (Pieters and Vlietinck 
2005). Fractionation of the crude plant extract could either be done using the different 
physical properties of solvents or using physical separation techniques such as 
 
 
 
 
chromatography which is by far the more common technique. Fractionation on a 
chromatographic column is effected using solvent mixtures that selectively separate 
compounds according to their different phytochemical classes (Harborne, 1998). The 
advantage of this technique is that it is a quick and simpler method for identifying and 
isolating only compounds that belong to the specific phytochemical class of interest.  Since 
most plants contain more than one compound belonging to the same phytochemical class, 
further fractionation is often required to separate and isolate each as a single pure 
compound. The fractionation process could also provide compounds that do not necessarily 
belong to the desired phytochemical class such as lipids and these would naturally have to 
be separated from the desired compounds for evaluation. After the initial extraction process 
of the plant the residue has to be chromatographed in order to separate each of the 
components in the extract for subjection to the identification process. Separation is carried 
out mainly using one or a combination of the following chromatographic techniques; 
column chromatography (CC), thin layer chromatography (TLC), gas liquid 
chromatography (GLC) and high performance liquid chromatography (HPLC). The choice 
of separation technique depends largely on the solubility profile and volatility of the 
compounds to be separated. Generally CC and TLC are preferred for water and lipid-
soluble compounds, while GLC is preferred for volatile compounds and HPLC for non-
volatile compounds such as terpenoids, phenolics, alkaloids and sugars (Harborne, 1998). 
Chromatographic separation is based on the differences in the partition coefficients of 
compounds within a mixture when they are allowed to partition between a stationary phase 
and a migrating solvent. Compounds highly soluble in the migrating solvent are transported 
faster while those less soluble are slower moving, with the most soluble compounds eluting 
 
 
 
 
first and the least soluble last. In TLC, the stationary phase comprises of a thin layer of 
absorbent material such as silica gel, polyvinylpyrrolidone, polyamide, and ion exchange 
resins, on a supportive base such as glass or aluminium. Separation takes place in a tank 
with the atmosphere saturated with the solvent, and the mobile phase is allowed to run up 
the plate starting just below the level of the mixture to be separated (Miller, 1975). TLC is 
a relatively cheap, fast and effective means for separating mixtures, but it is not very 
effective for separating compounds with similar chemical characteristics, or for very 
complex mixtures. TLC is also only useful for separating very small quantities of mixtures, 
though preparative TLC with a thicker absorbent layer could be used to separate larger 
quantities. Column chromatography satisfies this need for separating large quantities of 
materials. Silica gel packed into a cylindrical column acts as the stationary phase, while the 
mobile phase is used to elute the material packed at the top of the column. The mobile 
phase could either be moved by gravity or a low pressure pump. Column chromatography 
unfortunately suffers the same problem as TLC as it is sometimes unable to separate out 
quantities of pure compounds from a complex mixture. HPLC overcomes some of the 
problems associated with column chromatography.  In HPLC, the stationary phase is 
bonded to a porous polymer in a narrow-bore column made of stainless steel and the 
mobile phase passed through at high pressures (Hamilton and Sewell 1982). Unlike column 
chromatography, HPLC systems are usually computerised, allowing for a programmed 
change in the concentration of the constituents of the mobile phase, stringent monitoring 
and control of the chromatographic environment and also incorporation of various 
detectors to detect separated samples. HPLC systems are highly sensitive to impurities and 
are unsuitable for separating most crude plant extracts, usually requiring some pre-
 
 
 
 
treatment to remove most of the bulk impurities such as tannins that would otherwise clog 
the columns (Harborne, 1998). Unfortunately HPLC systems which are only designed to 
separate microgram quantities of samples at a time, are complex to operate and expensive 
compared to TLC and CC. GLC is similar to HPLC with the exception that the sample 
passes through a heated column as a gas, and an inert gas such as nitrogen or argon acts as 
the mobile phase. GLC, primarily only suitable for volatile compounds, is both expensive 
to run (Miller, 1975). One of the last stages of the isolation of the almost pure compound is 
re-crystallization. In a saturated and hot solution, pure crystalline matrixes of the 
compound form spontaneously, and this behaviour is taken advantage of to produce pure 
crystals of the isolated molecule in a suitable organic solvent.  
In practice, most researchers use a combination of these and other extraction and separation 
methods to isolate pure compounds from plants. In the current study solvent extraction, CC 
and TLC were utilised in the isolation of a pure diterpene from the leaves of L. leonurus.      
 
2.4 Identification of compounds  
Compounds isolated from plants could reasonably be expected to play a role as precursors 
for new bioactive molecules or as drugs themselves. However, before they can be utilized, 
they have to be properly identified and their properties fully evaluated. There are many 
methods available for the identification of chemical compounds present in a plant, but 
basically they all depend on the fact that all chemicals have unique physicochemical 
properties. Physical identification methods include melting point, Rf values from TLC, 
optical rotation and X-ray crystallography, while ultra violet (UV), infra red (IR), nuclear 
 
 
 
 
magnetic resonance (NMR) and mass spectroscopy (MS) identify the structures of the 
compounds using their spectral characteristics.  
Every compound possesses a unique melting point and this could be used to compare an 
unknown compound against possible reference compounds. It is however important to note 
that even small quantities of impurities could alter the melting point of a compound and so 
melting point alone cannot be used to identify compounds but rather as one of many tools. 
Rf values from TLC experiments can also be used in very few instances for the 
identification of a compound on a comparative basis only and never as a confirmation. Rf 
values are measured as the distance migrated by the compound on the stationary phase 
relative to the distance migrated by the solvent phase. Experiments are usually done on a 
TLC plate with a reference compound and the sample compound on the same plate, and 
exact Rf values could be an indication that they are similar compounds. Rf values are not 
definite as two compounds with very similar chemical structures may have the same Rf 
value. The UV spectra also contribute a limited role in the structural identification of a 
compound, but also have limitations similar to the other methods mentioned above. For a 
new compound, elucidation of the structure is vital to determining its novelty. The 
following methods are routinely used in structure elucidation. 
Infrared (IR) measurements are made between 4000 and 667 cm-1 in the electromagnetic 
spectrum. In IR spectroscopy, vibrations of individual bonds or functional groups within 
the compound under investigation appear as spectral bands or peaks above 1200 cm-1 that 
are distinct for each such bond or functional group.   Below 1200 cm-1spectral bands 
indicate vibration of the whole molecule. An advantage of IR spectroscopy is that spectra 
are simple to interpret and could be used to either determine functional groups contained in 
 
 
 
 
the compound or compare its spectrum to other known compounds for identification 
(Skoog and West 1971; Harborne, 1998).  
NMR spectroscopy works on the principle that certain atomic nuclei have spin and 
magnetic moment properties and exposure of these nuclei to a magnetic field would lead to 
a splitting of their energy levels. This molecular environment then influences absorption of 
radiation by the nuclei and the extent of absorption can be correlated with the molecular 
structure of the compound (Skoog and West 1971). NMR can only be used for compounds 
containing nuclei with an odd atomic number since these nuclei have a residual spin and 
include atoms such as 13C, 15N and 1H. Traditionally NMR is measured in a liquid state, 
with the compound dissolved in a solvent such as carbon tetrachloride or deuterated 
chloroform. NMR spectroscopy is usually done in 2 dimensions (2D) and among the 
different types of NMR analysis are: COSY, HMQC, HSQC, HMBC, HECTOR, TOCSY, 
NOESY and ROESY with each giving a different amount of structural information for an 
unambiguous structural assignment. Thus correlation spectroscopy (COSY) measures the 
frequency of those protons which are coupled to each other as off diagonal peaks that then 
correlate to their chemical shifts, and is used to analyse proton (1H) spectra (Keeler, 2006). 
Heteronuclear multiple quantum coherence (HMQC) measures 13C nuclei shifts that are 
correlated to the protons attached to them also as diagonal peaks on two separate frequency 
co-ordinates. Heteronuclear single quantum correlation (HSQC) spectra usually indicate 
single bond correlations between 13C and a proton, heteronuclear multiple-bond correlation 
(HMBC) spectra indicate all long range 13C – 1H or 15N – 1H couplings in the compound, 
and heteronuclear correlation (HECTOR) effects the same results as 13C-1H correlation 
spectra. Total correlation spectroscopy (TOCSY) is similar to COSY in that it observes 
 
 
 
 
protons only, but in addition also indicates protons connected by an unbroken chain of 
couplings. Nuclear overhauser effect spectroscopy (NOESY) is quite similar to COSY, but 
while COSY indicates which protons are in close proximity due to their coupling through 
bonding electrons, NOESY indicates which protons are located in close proximity to each 
other in the compound through non-bonding through space effects viz., interactions of 
small magnetic moments between protons near each other (Keeler, 2006). The NMR 
spectrometer comprises of a powerful magnet that supplies the magnetic field, a radio-
frequency source that supplies a plane-polarized beam perpendicular to the path of the 
magnetic field, and a signal detector surrounding the sample and at right angles to the 
radio-frequency source to detect radio-frequency signals produced by the resonating nuclei 
(Skoog and West 1971). To elucidate the structure of a compound using NMR, the pure 
compound in a solution is introduced into the instrument and the different spectra 
mentioned above obtained. Analysis of the spectra then builds up a composite picture of 
the compound. NMR spectroscopy is one of the most powerful tools for the elucidation of 
the structure of a compound, and like mass spectroscopy (MS) requires only a small 
quantity of the sample. The downside to NMR spectroscopy is that it is expensive, requires 
expertise to operate and can only be applied to pure samples.  
X-rays are part of the electromagnetic spectrum between gamma-rays and UV light, 
usually produced when a high velocity stream of electrons impact a metal target in an 
evacuated tube. X-rays are high energy, short wavelength beams suited to probing the 
structural arrangement of atoms and molecules (Harley and Wiberley 1954).Three X-ray 
methods are used in analytical chemistry to determine the chemical composition of a 
compound: X-ray powder-diffraction, X-ray fluorescent and X-ray absorption analysis. X-
 
 
 
 
ray fluorescent and absorption analysis depend on the absorption and fluorescent properties 
of a particular element and so are useful to identify elements, while X-ray diffraction 
analysis is able to determine the actual three dimensional structure of a compound. For 
complex compounds that are crystalline in nature, X-ray diffraction patterns are 
characteristic for both the form of the crystal and the spacing of the layers of the crystal 
lattice and hence its universal use in solving structural problems. In X-ray crystallography 
the integrated intensities of the diffraction peaks are used to reconstruct the electron density 
map within a unit cell of the crystal to give a structural picture of the crystalline compound. 
For structure elucidation, the single crystal diffractometer and a computer programme are 
used, while powder diffractions are suitable for compounds whose fingerprint is already 
known.       
In the identification and structural analysis of complex compounds, mass spectrometry has 
proven to be a powerful and versatile tool, perhaps as important and powerful as infrared or 
NMR spectroscopy. The basic principle of the mass spectrometer is that the impact of an 
electron stream on a given molecule produces a group of positive particles whose mass 
distribution is characteristic for the given molecule (Skoog and West 1971). In other words 
each molecule produces a particular unique fingerprint of its fragments. Samples 
undergoing mass spectroscopy experiments are first ionized using electrospray ionization 
(ESI) to allow for maximum impact with the electron stream. ESI is a liquid-phase ion 
source and ionizes the sample at atmospheric pressure before the ions are transferred into 
the mass spectrometer. In the mass spectrometer, positive ions are separated from negative 
ions and accelerated by means of a potential difference. Accelerated ions are then subjected 
to a strong magnetic field on a curved path which serves to focus ions of a particular mass 
 
 
 
 
to charge ratio (m/z) on a collector electrode. Varying the magnetic field changes the ions 
collected and spectra produced for the compound from which it may then be identified. 
Mass spectrometry is a very powerful tool for structural identification and analysis, but it is 
a complex and expensive equipment to operate. Its advantage over NMR is that most mass 
spectral data are easier to interpret, and also it provides the molecular weight of the 
compound (Skoog and West 1971).   
Hyphenated systems combining the chromatographic separation techniques described 
above and analytical instruments like NMR and MS are becoming very popular. Examples 
include gas chromatography-mass spectrometry (GC-MS), liquid chromatography-mass 
spectrometry (LC-MS) and liquid chromatography-nuclear magnetic resonance (LC-NMR) 
systems (Kite et al., 2003). These systems have the advantage of rapid and effective 
separation and identification of very complex mixtures, but are unfortunately still very 
expensive. For this study, NMR, IR, MS and X-ray crystallography were used to elucidate 
the structure of the diterpene isolated from the leaves of L. leonurus.  
 
2.5 Models in cardiovascular research  
Methods in cardiovascular research can broadly be classified as in vivo or in vitro 
depending on whether whole live animals, cells, tissues or organs are used. Some of the 
earliest experiments on the effects of compounds on the cardiovascular system were carried 
out in the late 19th century mostly using isolated frog hearts (Skrzypiec-Spring et al., 2007). 
Presently rats, mice, guinea pigs, rabbits and dogs are the preferred test subjects because as 
mammals, their cardiovascular systems are much more similar to that of humans than those 
 
 
 
 
of amphibians. For in vivo experiments, rats and mice are cheaper to breed than dogs, and 
are more robust than guinea pigs and rabbits. Rats unlike mice are big enough to enable 
easy handling during experiments, and unlike rabbits are very stable under anaesthesia 
(Livius et al., 2000). Examples of animal models used for in vivo cardiovascular 
experiments include the normotensive, spontaneously hypertensive, 2-Kidney 1-clip 
hypertensive, DOCA/salt hypertensive and salt-loaded hypertensive models. The 
normotensive rat model is ideal for pharmacologic screening where the actual 
cardiovascular effect of the substance is unknown because it allows for both hypertensive 
and hypotensive effects to be observed. To test for antihypertensive effects, a hypertensive 
model such as the spontaneously hypertensive, 2-Kidney 1-clip hypertensive, DOCA/salt 
hypertensive or salt-loaded hypertensive model is used. In vitro methods on the other hand 
involve the use of isolated organs, tissue or cells usually in an environment that simulates 
the natural physiological environment. Examples of preparations of parts of organs include 
rabbit ear artery, rat mesenteric artery, rat atrium, and rat or rabbit aorta preparations, while 
an example of the isolated perfused organ preparation for in vitro experiments is the 
isolated perfused heart system (Langendorff or working heart perfused) (Gross, 1994; 
Consolini and Sarubbio 2002). Cellular models for cardiovascular research include the 
loose patch clamp technique (Ruff, 1996; Zhang and Tan 1997). In vitro methods are 
generally used to study the effects of test substances on individual organs or parts of organs 
and help give a clearer idea of the actions of the test substances on the organ or cell in 
question. The models are usually preferred when elucidating the mechanism of action of 
test substances, but do not always give an accurate picture of the effect in a whole animal. 
 
 
 
 
For the present work the in vivo experimental model was chosen because it is easier to 
extrapolate results from this model to humans. The model is also able to measure the effect 
of test substances within the complex interactions of the nervous system as would occur in 
clinical practice, unlike isolated organ, tissue or cell models. The anaesthetized 
normotensive rat model was chosen since the cardiovascular effect of the test compound 
was unknown.  
 
The anaesthetized normotensive rat model allows the researcher to record changes in blood 
pressure and heart rate in intact animals, in response to administered drugs. The rat is 
anaesthetized with sodium pentobarbitone, injected intra-peritoneally, and the trachea 
exposed and cannulated for artificial respiration. To record changes in heart rate and blood 
pressure, the carotid artery, the abdominal aorta or the femoral artery is exposed and 
cannulated. The cannula is connected to a pressure transducer and thence to a suitable 
instrument to record changes in blood pressure and heart rate. Drug substances are infused 
via a cannula inserted into either the jugular or femoral vein (figure 2.3).  
 
 
 
 
 
 Figure 2.3: The anaesthetized normotensive rat model (a= BP transducer; b= arterial 
catheter; c= venous catheter; d= Oxygen mask; e= syringe pump; f= small animal 
operating table; g= computer running chart 5 software; h= male Wistar rat).  
 
 
One of the advantages of the anaesthetized normotensive rat model is that the experiment 
could run for more than 24 hours if the animals is suitably prepared and kept under 
anaesthesia (Hearse and Sutherland 1999). The anaesthetized normotensive rat model 
records changes in heart rate, systolic pressure, diastolic pressure and mean arterial 
pressure. Normal ranges are between 116mmHg – 145mmHg (systolic), 76mmHg – 
97mmHg (diastolic), 103mmHg – 129mmHg (mean arterial pressure) and 296 – 388pbm 
(heart rate) for a 300g rat (Livius et al., 2000). Male animals are preferred to female 
animals, and young rats are used instead of old ones. This is because in the older rats, the 
 
 
 
 
responsiveness of the heart to stimulation is reduced, the walls of the arteries are less 
elastic and as with humans, older rats tend to be spontaneously hypertensive (Hearse and 
Sutherland 1999).  
 
 
2.6 The cardiovascular system 
The cardiovascular system comprises of the heart – a four-chambered muscular pump that 
pumps blood around the body and a network of blood vessels made up of arteries, veins, 
arterioles, venules and capillaries. This complex system is designed to deliver nutrients to 
the organs, tissues and cells of the body and to remove metabolic waste to their sites of 
excretion. The heart is auto-rhythmic in that the rhythmic pumping action is controlled by 
impulses generated within the heart itself, with certain muscle cells within the heart 
specially adapted to spontaneously generate and rapidly transmit the electrical impulses 
that produce the cycles of contraction and relaxation. Two nodes or clusters of these cells 
are located within the walls of the right atrium: the sinoatrial (SA) node and the 
atrioventricular (AV) node (Rang et al., 2007). The SA node acts as the pacemaker of the 
heart, while the AV node conducts generated impulses rapidly to the left and right 
ventricles. In myocardial cells within the ventricles, the impulse causes a rapid 
depolarization of the cell membrane due to the rapid influx of Na+ through voltage gated 
channels. This is followed by a gradual influx of Ca2+ leading to a sustained depolarization 
and then repolarization by efflux of K+. The presence of the slow inward calcium current 
distinguishes cardiac cells from neuronal cells and enables the rhythmic contraction of the 
ventricles (Fozzard, 2002). Contraction of the ventricles drives blood from the heart into 
the systemic circulation. Apart from the intrinsic rhythmicity of the heart dictated by the 
 
 
 
 
pacemaker, the heart is also subject to regulation through neural control via the sympathetic 
and parasympathetic nervous systems and hormonal control through the release of 
adrenaline and noradrenaline from the adrenal medulla (Hoffman, 1998a).     
Sympathetic control of cardiac rhythm is through post ganglionic nerve fibers that 
innervate the SA and AV nodes, coronary vessels, atria and ventricular myocardium. 
Sympathetic stimulation leads to the release of noradrenaline, the neurotransmitter in the 
postganglionic synapse and its agonist effect on β1-adrenergic receptors on the myocardial 
cell surface leads to an increase in heart rate (a positive chronotropic effect) and force of 
contraction (a positive inotropic effect). β1 receptors in the heart mediate neural and 
hormonal regulation of the heart. Stimulation of these receptors with an agonist drug would 
lead to a positive chronotropic and inotropic effect, while inhibition of these receptors with 
an antagonist would lead to a negative chronotropic and inotropic effect. Parasympathetic 
control of cardiac rhythm is via the vagus nerve which also innervates the SA and AV 
nodes, coronary vessels, atria and ventricular myocardium. Parasympathetic stimulation 
releases acetylcholine which acts on M2 receptors and results in a decrease in activity of the 
SA node, impulse conduction through the AV node, atrial contractility and force of 
ventricular contraction. The net effect is a negative chronotropic and (to a lesser degree) a 
negative inotropic effect. Sympathetic stimulation can increase cardiac output by 50% - 
100% of the resting values, while parasympathetic stimulation can decrease it by 10% - 
20%. The resting heart rate is controlled by a balance of sympathetic and hormonal 
stimulation and the opposing parasympathetic vagal tone (Hoffman, 1998a).  
 
 
 
 
Blood vessels that carry blood from the heart to tissues and cells are called arteries. 
Arteries are hollow tubes surrounded by contractile cells that contract to narrow and relax 
to increase the lumen size through which blood flows. Blood pressure (BP) measures the 
force that blood flowing through the arteries exerts on the walls of the arteries. BP rises and 
falls with contraction and relaxation of the ventricles, with the maximum pressure known 
as systolic pressure (SP) coinciding with ventricular contraction and the minimum pressure 
known as diastolic pressure (DP) coinciding with ventricular relaxation. The force exerted 
by blood on the vessel walls depends on the quantity of blood flowing through the vessels – 
determined by cardiac output (CO) and the resistance of the vessel walls to the stretching 
effect of the pressure – peripheral vascular resistance (PVR). The relationship between BP, 
CO and PVR can be expressed as:   
                                                 BP = CO x PVR  
CO is the volume of blood pumped by the heart into the systemic circulation per unit of 
time and is dependent on heart rate (HR) and the volume of blood pumped out into 
systemic circulation with each contraction of the ventricles – stroke volume (SV). The 
relationship between CO, SV and HR is expressed as: 
                                                 CO = SV x HR 
As can be inferred from the above equations, PVR plays a huge role in determining blood 
pressure. One aspect of blood pressure not yet mentioned is the effect of the venous 
system. The walls of veins are not as muscular as those of arteries and so do not contribute 
a lot to total PVR. Venous return - the flow of blood back to the heart, however has a direct 
effect on stroke volume, which then determines CO. Venous pooling reduces venous return 
and so reduces stroke volume, eventually leading to a reduction in blood pressure as seen 
 
 
 
 
from the above equations.  Dilatation of the veins would lead to a pooling of blood in the 
larger veins, leading to a decrease in preload. A significant decrease in preload would lead 
to a decrease in force of contraction (because of a decrease in the stretching of the 
ventricular walls), stroke volume and cardiac output (Seeley et al., 2003). Constriction of 
the veins would lead to an increase in blood flow to the heart, leading to an increase in 
preload. The increase in preload then leads to an increase in force of contraction, stroke 
volume and cardiac output.  
The contractile walls of arteries are innervated by sympathetic nerves and contain α1 and β2 
receptors which in addition to α2 receptors found in presynaptic end plates mediate 
sympathetic regulation of the peripheral vascular resistance. Adrenaline and noradrenaline, 
the neurotransmitters in the sympathetic nervous system act on these receptors to control 
vascular resistance in the arteries. Activation of α1 receptors by noradrenaline leads to 
vasoconstriction via an increase in intracellular Ca2+ in smooth muscle cells. Stimulation of 
α2 and β2 receptors leads to vasodilatation, with α2 receptor stimulation inhibiting the 
release of neurotransmitters for the synapse. As can be seem from the above, blood 
pressure is determined by a complex interaction between the sympathetic and 
parasympathetic nervous system and mediated by  β1 and M2 receptors in the heart 
controlling heart rate and cardiac output, and α1, α2 and β2 receptors in the arteries 
mediating peripheral vascular resistance. Changes in blood pressure reflect changes in one 
or more of these parameters, and the cardiovascular effect of any compound is determined 
by its agonist or antagonist effect on one, some or all of these receptors (Benowitz, 1998).    
  
 
 
 
 
 
 
2.7 Drugs acting on the cardiovascular system 
As can be inferred from the above discussion, drugs can also alter the normal functioning 
of the cardiovascular system through their effects as agonists or antagonists on the 
sympathetic and parasympathetic nervous system innervating the heart and blood vessels. 
The drugs could be broadly classified as chronotropic, inotropic and vasoactive agents. 
Chronotropic agents act on the myocardium to increase or decrease the heart rate – a 
positive or negative effect. The increase in heart rate (positive chronotropic effect) is 
achieved either by an agonist effect on β1 receptors in the heart, or by a decrease in vagal 
tone, while the decrease in heart rate (negative chronotropic effect) is achieved by either an 
inhibitory effect on β1 receptors in the heart, or by blockade of Ca2+ channels in cardiac 
myocytes or by increasing vagal tone. Positive chronotropic agents that act via an agonistic 
effect on β1 receptors include adrenaline, noradrenaline, isoproterenol and dobutamine, 
while atropine antagonizes the effect of the parasympathetic neurotransmitter 
acetylcholine. Negative chronotropic agents acting via β1blockade include β blockers like 
propranolol and atenolol, while verapamil, nifedipine and diltiazem block Ca2+ channels by 
preventing the opening of voltage-gated L-type calcium channels (Rang et al., 2007).    
Inotropic agents alter the contractility of the myocardium to either increase (a positive 
effect) or decrease (a negative effect) the force of ventricular contraction and in so doing 
stroke volume. Contractility of the heart is dependent on intracellular Ca2+, and the entry of 
Ca2+ into cardiac cells is dependent on the opening of voltage gated Ca2+ channels and 
intracellular Na+ concentration. Positive inotropic agents increase intracellular Ca2+ and 
include adrenaline, noradrenaline, dobutamine, cardiac glycosides, dopamine and 
isoproterenol. Negative inotropic agents prevent the entry of Ca2+ into myocardial cells and 
 
 
 
 
include the Ca2+ channel blockers mentioned above, and the β blockers propanolol and 
atenolol. As is evident from the above, some drugs possess both chronotropic and inotropic 
effects on the heart.   
As previously mentioned, peripheral vascular resistance plays a huge role in determining 
blood pressure. Certain agents called vasoactive agents could cause the constriction or 
dilatation of blood vessels by either acting on α1, α2, and β2 receptors or altering the release 
of the neurotransmitter noradrenaline into synaptic cleft. Phenylephrine and methoxamine 
would act as agonists on α1 receptors and cause vasoconstriction consequently increasing 
the blood pressure, while on the other hand α1 receptor antagonists such as prazosin and α2 
receptor agonists such as clonidine would produce vasodilatation. Reserpine which 
depletes vascular stores of the catecholamines adrenaline and noradrenaline, and 
methyldopa which prevents catecholamine synthesis would also produce vasodilatation. 
For non-selective alpha receptor (α1 and α2) antagonists, the vasodilatation produced by α1 
blockade is accompanied by reflex tachycardia due to the increased release of the 
neurotransmitter noradrenaline (Rang et al., 2007). Reflex tachycardia could also be due to 
intrinsic mechanisms monitoring blood pressure such as the baroreceptor reflex. Certain 
pressure receptors found around the aortic arch detect increases in blood pressure and via 
an increase or decrease in parasympathetic activity in the heart decrease or increase the 
heart rate. This mechanism is meant to keep blood pressure within normal limits, but when 
drugs are used to change cardiac parameters, could alter the results of the drugs’ effect on 
the cardiovascular system.  
Drugs acting on the cardiovascular system would produce the observed effects through any 
of the mechanisms mentioned above. With novel compounds exhibiting cardiovascular 
 
 
 
 
activity, the mechanism of action could be the result of interactions with any of the 
receptors listed above, or could involve cellular processes such as the opening or closing of 
ion channels or the synthesis or inhibition of certain chemical mediators like cyclic 
adenosine monophosphate (cAMP). 
 
The increase in reliance on traditional medicines, the rejuvenation of interest in plant 
medicines as a potential source of new drug compounds and the need for the 
pharmacologic analysis of plants in use as traditional medicines have lead to increased 
research on plants used in traditional medicine. Despite recent interest in plant medicines, 
there are still a large number of plants used in traditional medicines that are yet to be 
scientifically studied. The traditional use of a plant could serve as a pointer to possible 
therapeutic effects of compounds isolated from it, and these plants could yield novel 
compounds that could be useful as new drugs, or precursors in the development of new 
drugs for the management or cure of diseases. L. leonurus has widespread use in traditional 
medicine for treating cardiovascular diseases, and extracts of the plant have been reported 
to produce cardiovascular effects. Since L. leonurus contains compounds belonging to 
phytochemical classes that exhibit cardiovascular effects, it could yield individual 
compounds with cardiovascular effects. If such cardioactive compounds exist in the 
extracts of the plant, then an understanding of the mechanism of action of the effect of the 
compounds may bring us closer to a new drug for the treatment of cardiovascular diseases. 
 
 
 
HYPOTHESIS 
 
 
 
 
The plant L. leonurus used in traditional medicine for the treatment of cardiovascular 
diseases contains pure compound(s) that on their own possess cardiovascular effect. 
 
AIMS AND OBJECTIVES 
This study aims to: 
- Isolate and characterize one compound from L. leonurus that exhibits 
cardiovascular effects. 
- Determine the possible mechanism(s) by which the isolated compound exhibits its 
cardiovascular effect. 
 
 
 
 
 
 
 
 
CHAPTER THREE 
 
 
 
 
Materials and methods 
Equipment and chemicals used in the study are listed in this chapter. Also described are the 
different methods employed in the isolation, structure elucidation and in vivo assessment of 
the compound. 
3.1 Materials used in extraction and identification 
3.1.1 Chemicals 
a) Hexane (b.p. 65-70oC) (Kimix, Cape Town, South Africa)  
b) Ethyl acetate (distilled prior to use) (Kimix, Cape Town, South Africa)  
c) Silica gel (35-60 mesh and 70-230 mesh) (Sigma-Aldrich, Steinheim, Germany)  
d) Methanol (Sigma-Aldrich, Steinheim, Germany)  
e) Concentrated HCl (Kimix, Cape Town, South Africa) 
f) Chloroform (Kimix, Cape Town, South Africa) 
g) Ammonia (Kimix, Cape Town, South Africa) 
h) Anhydrous magnesium sulphate (Kimix, Cape Town, South Africa) 
i) Acetic acid glacial (Kimix, Cape Town, South Africa) 
j) Trichloromethane –d (CDCl3) (Merck, Johannesburg, South Africa)  
k) Nujol IR grade (Merck, Johannesburg, South Africa) 
l) Acetonitrile (Merck, Johannesburg, South Africa) 
m) Distilled water 
 
3.1.2 Equipment 
 
 
 
 
I) Equipment used in extraction 
a) Soxhlet apparatus 
b) Heating mantle 
c) Grinder  
d) TLC aluminum sheets Silica gel 60 F254; 20 x 20cm (Merck, Johannesburg, SA)  
e) Low pressure column chromatography system: Glass column; Minipuls 3 peristaltic 
pump; UV detector 112; fraction collector FC203B (all Gilson, Middleton, USA) 
 f) Rotovapour (Bibbly Sterilin, England) 
 
II) Equipment used in identification  
a) Bellingham & Stanley ADP 220 polarimeter (Tunbridge Wells, England) 
b) Perkin-Elmer Paragon 1000 PC IR spectrometer (Waltham, MA, USA) 
c) Varian UnityInova 600 NMR spectrometer (Palo Alto, CA, USA) 
d) Waters API X-TOF Ultima mass spectrometer (Milford, MA, USA) 
e) Gallenkamp melting point equipment (Leicestershire, England) 
f) Siemens SMART diffractometer (Madison, WI, USA) 
 
 
 
 
3.2 Materials used in the anaesthetized normotensive rat model  
3.2.1 Drugs and Chemicals 
 
 
 
 
a) Atenolol (Astra Zeneca, Sunninghill, South Africa) 
b) Prazosin (Sigma-Aldrich, Steinheim, Germany) 
c) Dobutamine (Intramed, Porth Elizabeth, South Africa) 
d) Reserpine (Sigma-Aldrich, Steinheim, Germany) 
e) Verapamil (Sigma-Aldrich, Steinheim, Germany) 
f) Sodium pentobarbitone (Kyrn Laboratories, Johannesburg, South Africa) 
g) Heparin (Intramed, Porth Elizabeth, South Africa) 
h) Tween 80 (Sigma-Aldrich, Steinheim, Germany) 
i) K-Y jelly (Johnson & Johnson, Midrand, South Africa)      
j) Normal saline 
 
3.2.2 Equipment 
a) Small animal operating table (BioScience, Cape Town, South Africa)  
b) Blood pressure transducer (AD instruments, Bella Vista, Australia)  
c) Power Lab 4/20T (AD instruments, Bella Vista, Australia)  
d) Chart 5 for windows (AD instruments, Bella Vista, Australia) 
d) BP amplifier (AD instruments, Bella Vista, Australia)   
e) Syringe pump (Ascor AP22, CA, USA)  
f) Oxygen mask 
 
 
 
 
 3.2.3 Animals  
Male Wistar rats aged between 3 and 4 months were used to assess the cardiovascular 
effects of the isolated compound. Rats were used because they provide a better compromise 
between size and heart rate than rabbits which although larger in size, have a higher resting 
heart rate. In spite of the fact that some researchers have suggested that there are no gender 
specific differences in cardiovascular parameters for the rats, only male Wistar rats were 
used to ensure uniformity (Livius et al., 2000). The age range of 3-4 months was chosen 
because that appears to be the optimal age for male Wistar rats. Older rats have lower heart 
rates and a reduced sensitivity to cardioactive substances, probably due to loss of elasticity 
in the arteries which occurs with age (Livius et al., 2000). 
 
3.3 Methods 
3.3.1 Extraction  
The stems and leaves of Leonotis leonurus were collected from Montague Botanic 
Gardens, Cape Town, South Africa, and a voucher specimen (No. 6859) deposited at the 
herbarium of the University of the Western Cape. The fresh leaves of the plant were 
washed with distilled water, dried at 30°C in a ventilated oven for 72 hours, and ground 
into a fine powder. The soxhlet apparatus was used to extract 183 g of the ground leaves in 
methanol over a period of 24 hours and the resulting extract was filtered through a filter 
paper to remove small solid particles. The rotovapor was used to remove excess solvent in 
vacuo to afford a thick dark brown residue. Distilled water was added to the residue and the 
 
 
 
 
resulting solution was acidified using concentrated HCl, and exhaustively extracted with 
chloroform. The acidified solution was then basified with concentrated ammonia, and 
sequentially exhaustively extracted with ethyl acetate followed by chloroform. Analytical 
TLC chromatography of the three extracts on aluminum backed TLC plates containing F254 
dye using a mobile phase made of a mixture of ethyl acetate: hexane (2:3) was carried out 
to determine if the extracts contained similar fractions as indicated by similar TLC profiles. 
The three extracts were then combined and dried with anhydrous magnesium sulphate, and 
after filtration, the solvent was removed under reduced pressure.  
The resulting residue was fractionated using low pressure column chromatography with 
silica gel (70–230 mesh grade) as the stationary phase and ethyl acetate: hexane (1:4) as 
eluent. Fractions as identified by the UV recorder were collected using a fraction collector 
and those displaying a similar TLC profile were combined to yield a total of 7 fractions. 
The fraction containing the greatest number of compounds (fraction 3) was then re-
chromatographed on the low-pressure column chromatography column using ethyl acetate: 
hexane: acetic acid as the eluent in the following sequential combinations: 
i) Ethyl acetate: Hexane: Acetic acid (3:2:1)  
ii) Ethyl acetate: Hexane: Acetic acid (3:2:0.5) 
iii) Ethyl acetate: Hexane: Acetic acid (3:1:0.5)   
The pure bands as indicated on the UV recorder were collected using the fraction collector, 
and further purified using preparative TLC plates with a mixture of ethyl acetate: hexane: 
methanol (3:1:0.5) and 0.5% glacial acetic acid as mobile phase. The separated bands were 
then scrapped off the TLC plates, dissolved in the mobile phase and silica gel filtered off. 
The solvent was then removed using the rotovapor and the residue re-dissolved in 
 
 
 
 
chloroform and allowed to evaporate very slowly to deposit pure crystals (1.53 g) of the 
diterpenoid: (13S)-9α, 13α-epoxylabda-6(19),15(14)diol dilactone. 
 
3.3.2 Physical properties of the isolated diterpenoid. 
 Melting point 
Melting point was determined using the Gallenkamp melting point apparatus. The average 
reading from four experiments was taken as the melting point of the compound. 
 
Optical rotation 
Optical rotation of a sample of the isolated diterpene to light (wavelength of the D line of a 
sodium source) at 19oC was measured using a Bellingham & Stanley ADP 220 polarimeter.   
 
Infra red (IR) spectroscopy  
The sample was made up with nujol and IR spectra recorded on a Perkin-Elmer Paragon 
1000 PC spectrometer that was corrected against an air background. 
Nuclear magnetic resonance (NMR) spectroscopy 
1H, 13C, 1H-1H COSY, HSQC, HMBC, DEPT and NOESY NMR spectra were collected on 
a Varian UnityInova 600 NMR spectrometer (Palo Alto, CA, USA) at 25 °C. 1H and 13C 
NMR spectra expressed in δ (ppm) were referenced to tetramethylsilane (TMS). 
 
 
 
 
 
X-ray crystallography  
Single-crystal X-ray diffraction analysis of the compound was carried out using the 
Siemens SMART diffractometer (Madison, WI, USA) at room temperature using graphite 
monochromated Mo Kα radiation.   
 
 Mass spectroscopy (MS) 
An ESI high impact mass spectrum of the compound dissolved in acetonitrile was obtained 
on the Waters API X-TOF Ultima LC-MS equipment at 350oC. 
 
3.3.3 Anaesthetized normotensive rat model 
Healthy male Wistar rats aged between 3 and 4 months, and within the weight range 
between 250 g and 400 g were used for the in vivo study of the compound. The animals 
were weighed and anaesthetized with sodium pentobarbitone (40 mg/kg) injected by intra-
peritoneal route. Anaesthetized animals were then transferred to a small animal operating 
table and restrained. A midline incision was made in the throat region to access the trachea, 
and an incision made into the trachea.  A lubricated hollow tracheal tube was carefully 
inserted into the trachea through the incision and secured in place with a knot. The tracheal 
tube was cleared of fluids, and an oxygen mask placed over the head and throat region to 
facilitate breathing.  
The external jugular vein was then exposed, excess tissue carefully cleaned off it and 
clamped at the end proximal to the heart with a bulldog clamp to prevent blood loss. The 
exposed section was then filled with blood by gently massaging the head, and tied off at the 
 
 
 
 
end proximal to the head. An incision was made into the vein, and a catheter lubricated 
with K-Y jelly and filled with a 10% heparin solution was carefully inserted into the vein 
and secured in place. The lower abdominal region was opened and the femoral artery 
carefully separated from the accompanying vein, nerve and tissue. The artery was tied off 
at the distal end and clamped with the bulldog at the proximal end. An incision was made 
into the artery between the tied end and the clamp, and a lubricated catheter filled with a 
10% heparin solution carefully inserted and secured with a knot. The bulldog clamp was 
then carefully removed to allow for blood flow into the catheter.  Care was taken to make 
sure that the arterial catheter did not block the branch-off of the renal artery from the aorta. 
Incisions were cleaned, sutured using catgut sutures, covered with gauze and kept moist for 
the duration of the experiment. A temperature probe was inserted into the rectum to 
monitor the animal’s temperature throughout the experiment. Adjustments to body 
temperature were done by either increasing or decreasing the heating on the small animal 
operating table to keep rectal temperature at 37.3±0.5oC. After surgery, animals were 
allowed a 30 minute recovery period before the commencement of experiments. During the 
recovery period, blood pressure calibrations were done on the chart 5 software and 
recording of parameters started. After the 30 minute stabilization period, animals whose 
blood pressure and heart rate readings were beyond the normal ranges (systolic pressure 
116mmHg – 145mmHg; diastolic pressure 76mmHg – 97mmHg; mean arterial pressure 
103mmHg – 129mmHg; and heart rate 296 – 388bpm) were excluded from the 
experiments (Livius et al., 2000). A syringe pump was used to infuse drugs at a constant 
rate (0.3 ml/min) through the venous cannula. A sufficient recovery period between 
 
 
 
 
individual doses was allowed to let cardiovascular parameters return to their baseline 
values. 
 
3.3.4 Drugs administered 
To determine the doses of the drugs to be used, animals were divided into 6 groups, with 
each group of 8 animals receiving one of the drugs listed below.  
a) Group I [(13S)-9α, 13α-epoxylabda-6(19),15(14)diol dilactone]: Dose-response curve 
(0.5 – 5.0 mg/kg).  
b) Group II (Reserpine): Dose-response curve (0.01 – 1.0 mg/kg).  
c) Group III (Prazosin): Dose-response curve (0.5 – 10.0 mg/kg).  
d) Group IV (Atenolol): Dose-response curve (0.5 - 3.0 mg).  
e) Group V (Dobutamine): Dose-response curve (30 – 90 µg/kg) 
f) Group VI (Verapamil): Dose-response curve (0.25 – 5.0 mg/kg) 
 
To elucidate the mechanisms via which (13S)-9α, 13α-epoxylabda-6(19),15(14)diol 
dilactone produced its effect, animals were divided into 5 groups, with each group 
consisting of 8 animals. The following protocols were used to infuse the isolated diterpene 
and standard drugs combinations for each group.   
a) Group VII: Reserpine (0.5 mg/kg) then (13S)-9α, 13α-epoxylabda-6(19),15(14)diol 
dilactone (0.5 mg/kg – 5.0 mg/kg). 
A baseline effect of the compound was first determined and then reserpine (0.5 
mg/kg) administered. A time period (6 hours) was allowed for sufficient depletion 
of vascular stores of catecholamines, and the isolated compound re-administered. 
 
 
 
 
b) Group VIII: Prazosin (7.0 mg/kg) then (13S)-9α, 13α-epoxylabda-6(19),15(14)diol 
dilactone (0.5 mg/kg – 5.0 mg/kg). 
Each dose of the isolated compound was administered immediately after the 
administration of prazosin. 
c) Group IX: Atenolol (2.0 mg/kg) and (13S)-9α, 13α-epoxylabda-6(19),15(14)diol 
dilactone (0.5 mg/kg – 5.0 mg/kg).  
Each dose of the isolated compound was administered 12-15 minutes after the 
administration of atenolol. 
d) Group X: Dobutamine (75 µg/kg) and (13S)-9α, 13α-epoxylabda-6(19),15(14)diol 
dilactone (0.5 mg/kg – 5.0 mg/kg).  
Each dose of the isolated compound was administered immediately after the 
administration of dobutamine. 
e) Group XI: Verapamil (4.0 mg/kg) and (13S)-9α, 13α-epoxylabda-6(19),15(14)diol 
dilactone (0.5 mg/kg – 5.0 mg/kg).  
Each dose of the isolated compound was administered immediately after the 
administration of verapamil. 
 
The effects of the compound and the standard drugs on systolic pressure (SP), diastolic 
pressure (DP), mean arterial pressure (MAP) and heart rate (HR) were evaluated.  
 
3.4 Statistical analysis 
 
 
 
 
The means of actual values for systolic pressure (SP), diastolic pressure (DP), mean arterial 
pressure (MAP) and heart rate (HR) from the experiments are reported. The difference 
between the baseline value of the parameters assessed and the maximum response obtained 
with the administration of (13S)-9α, 13α-epoxylabda-6(19),15(14)diol dilactone or standard 
drugs was calculated and expressed as a percentage of the baseline value (percentage 
change).  The percentage change in the value of the parameters obtained with the 
administration of (13S)-9α, 13α-epoxylabda-6(19),15(14)diol dilactone following the 
administration of standard drugs was also calculated and expressed as a percentage of 
maximum response obtained with the standard drugs. Percentage change of the difference 
between the maximum response obtained with the administration of (13S)-9α, 13α-
epoxylabda-6(19),15(14)diol dilactone alone and the maximum response obtained with the 
administration of (13S)-9α, 13α-epoxylabda-6(19),15(14)diol dilactone in animals pre-
treated with standard drugs was calculated.  Mean change was calculated and statistically 
analyzed using the student’s t test for significant difference (p<0.05).  
 
 
 
3.5 Ethical considerations 
The animals were allowed free access to food and water and all experiments were 
conducted in accordance with regulations as stipulated by the University of Western Cape 
concerning animal experiments.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER FOUR 
Results 
The results of the structure elucidation experiments of the tested compound isolated from 
Leonotis leonurus are presented in this chapter. Cardiovascular effects of the compound in 
anaesthetized normotensive male Wistar rats, as well as the results of experiments in 
animals pre-treated with the following standard drugs: reserpine, atenolol, prazosin, 
 
 
 
 
dobutamine, and verapamil are also presented. Dose-response curves for all standard drugs 
administered are also presented here. 
 
Following the extraction and fractionation processes described in the previous chapter, 
crystallization from chloroform yielded 1.53 g of a colourless, crystalline compound with 
melting point 162.9 – 164.2oC and optical rotation [α]19D +14.1 (c 0.78, CHCl3) (Obikeze et 
al., 2008). The isolated yield for the compound was 0.83%, and TLC on aluminium backed 
plates containing F254 dye with an ethyl acetate: hexane: (3:2) combination as mobile phase 
yielded a single spot with an Rf value of 0.53.  
 
4 .1 Structure elucidation  
The infrared spectrum of the isolated compound as a Nujol mull indicated strong bands at 
3626, 2909, 1770, 1462, 1374, 1196, 1100, 994, and 911 cm–1 (Appendix I). 1H, 13C, 1H-1H 
COSY, HSQC, HMBC, DEPT and NOESY NMR spectra collected on a Varian 
UnityInova 600 NMR spectrometer at 25°C were used in structure elucidation. Data from 
the 1H and 13C spectra is given below, while appendixes II – XXXV contain the full NMR 
spectra of the compound.  
 
1H NMR (CDCl3, 600MHz): δ 4.70 (1H, dd, J=4.6, 5.7 Hz, H-6), 4.38 (1H, ddd, J=6.0, 
7.2, 9.0 Hz, H-15a), 4.20 (1H, ddd, J=6.3, 7.2, 9.0 Hz, H-15b), 2.46 (1H, ddd, J=6.3, 7.2, 
13.3 Hz, H-16a), 2.27 (3H, m, H-11a, H-12a, H-16b) , 2.17 (3H,m,H-5, H-7eq, H-8), 2.09 
(3H, m, H-1eq, H-3eq, H-12b), 1.90 (1H, ddd, J = 4.2, 12.2, 18.3 Hz, H-11b), 1.73 (1H, m, 
H-2eq), 1.65 (1H, m, H-7ax), 1.56 (1H, m, H-2ax), 1.45 (1H, dt, J = 5.1, 14.4 Hz, H-3ax), 
 
 
 
 
1.28 (3H, s, H-18), 1.19 (1H, dt, J=8.2, 13.2 Hz, H-1ax), 1.05 (3H, s, H-20) and 0.91 (3H, 
d, J = 6.1 Hz, H-17). 
 
 
13C NMR (CDCl3, 150 MHz): δ 183.8 (C, C-19), 171.4 (C, C-14), 93.5 (C, C-9), 83.6 (C, 
C-13), 76.1 (CH, C-6), 65.0 (CH2, C-15), 45.8 (CH, C-5), 44.1 (C, C-4), 39.3 (C, C-10), 
37.3 (CH2, C-16), 34.3 (CH2, C-12), 32.2 (CH2, C-7), 31.5 (CH, C-8), 29.3 (CH2, C-11), 
28.3 (CH2, C-3), 27.8 (CH2, C-1), 23.8 (CH3, C-20), 23.1 (CH3, C-18), 17.9 (CH2, C-2) and 
17.5 (CH3, C-17). 
 
The three dimensional (3D) X-ray crystallography structure of the compound obtained 
from X-ray diffraction spectroscopy using the Siemens SMART diffractometer is given in 
Figure 4.1. High-resolution electron impact mass spectroscopy (HREIMS) on a Waters API 
X-TOF Ultima indicated a [M+H]+ ion at m/z 349.2009, which correlates with the 
molecular formula C20H29O5 (calculated for C20H29O5: 349.2015) (appendix XXXVI). 
Following convention, the compound was named (13S)-9α, 13α-epoxylabda-6β(19),15(14) 
diol dilactone (EDD) and figure 4.2 shows its chemical structure and numbering. 
 
 
 
 
 
Figure 4.1: 3D structure of (13S)-9α, 13α-epoxylabda-6β(19),15(14)diol dilactone. 
 
 
Figure 4.2: Chemical structure of (13S)-9α, 13α-epoxylabda-6β(19),15(14)diol 
dilactone (Obikeze et al., 2008). 
 
Scalar couplings measured in the 1H NMR spectrum and also from correlations observed in 
the 2D NOESY spectrum are shown below in figure 4.3. 
 
Figure 4.3: NOE correlations for (13S)-9α, 13α-epoxylabda-6β(19),15(14)diol 
dilactone. 
 
4 .2 Results of cardiovascular experiments  
 
 
 
 
The anaesthetized normotensive rat model was used to study the effects of all the drugs 
administered IV on the following cardiovascular parameters: systolic pressure (SP), 
diastolic pressure (DP), mean arterial pressure (MAP) and heart rate (HR). The 
cardiovascular effect of EDD was determined using 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 3.0 
mg/kg, 4.0 mg/kg and 5.0 mg/kg doses of the compound. Doses above 5.0 mg/kg resulted 
in the death of most animals and so were discontinued. Dose-response curves of the 
following standard drugs: reserpine (0.01 – 1.0 mg/kg), prazosin (0.5 – 10.0 mg/kg), 
atenolol (0.5 – 3.0 mg/kg), dobutamine (30 – 90 µg/kg) and verapamil (0.25 – 5.0 mg/kg) 
were also obtained using the same cardiovascular model. For each standard drug 
administered, the dose which elicited 80% of the maximum response obtained on the dose-
response curves was used to pre-treat animals before administration of EDD.  
 
Results obtained for the different substances administered are presented below in the form 
of graphs and tables. The graphs give the actual baseline blood pressure and heart rate 
readings of the values obtained after administration of the standard drugs and EDD, while 
the percentage change in these parameters with the administration of EDD in pre-treated 
and non pre-treated animals is also presented in the tables. Tables showing the percentage 
of the difference in the values of the parameters for EDD administered in pre-treated 
animals compared to the values of the parameters for EDD administered in non pre-treated 
animals are presented. However the percentage change in the parameters assessed for dose-
response experiments compared with the standard drugs is not presented because this is not 
the focus of the present study.  
 
 
 
 
 4.2.1 Dose-response for the cardiovascular effects of (13S)-9α, 13α-epoxylabda-
6β(19),15(14)diol dilactone (EDD) 
4.2.1.1 Effect on systolic pressure (SP) 
Figure 4.4 shows the effect of EDD (0.5 mg/kg – 5.0 mg/kg) on SP. EDD at the lower 
doses (0.5 mg/kg – 2.0 mg/kg) produced slight decreases in SP, which were neither dose-
dependent nor statistically significant when compared to the control readings of 
128.0mmHg ± 4.8. With the higher doses (3.0 mg/kg – 5.0 mg/kg) EDD produced 
statistically significant, dose-dependent increases in SP when compared to the control. The 
3.0 mg/kg dose induced a 29.7% increase in SP (from 128.0mmHg ± 4.8 to 166.0mmHg ± 
2.6), the 4.0 mg/kg induced a 34% increase in SP (from 128.0mHg ± 4.8 to 171.5mmHg ± 
7.8), and the highest dose induced a 35.8% increase in SP (from 128.0mmHg ± 4.8 to 
173.0mmHg ± 5.1) (figure 4.4 and table 1).   
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Figure 4.4: Effect of (13S)-9α,13α-epoxylabda-6β(19),15(14)diol dilactone on systolic 
pressure.  
* indicates statistical significance. 
 
4.2.1.2 Effect on diastolic pressure (DP) 
The lower doses of EDD induced dose-dependent decreases in DP (from 78.0mmHg ± 4.7 
to: 75.6mmHg ± 1.7; 73.1mmHg ± 3.8; and 72.9mmHg ± 4.1 for the 0.5 mg/kg; 1.0 mg/kg 
and 2.0 mg/kg doses respectively), which were not statistically significant when compared 
to the control (78.0mmHg ± 4.7) (figure 4.5). The higher doses of EDD however induced 
dose-dependent statistically significant increases in DP. The 3.0 mg/kg dose increased DP 
by 37.2% (from 8.0mmHg ± 4.7 to 107mmHg ± 4.8), the 4.0 mg/kg dose by 49.6% (from 
78.0mmHg ± 4.7 to 116.7mmHg ± 9.1) and the 5.0 mg/kg dose by 51% (from 78.0mmHg 
± 4.7 to 117.8mmHg ± 7.1) (figure 4.5 and table 1).  
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Figure 4.5: Effect of (13S)-9α,13α-epoxylabda-6β(19),15(14)diol dilactone on diastolic 
pressure.  
 
 
 
 
* indicates statistical significance. 
 
4.2.1.3 Effect on mean arterial pressure (MAP) 
Changes to MAP with the administration of EDD are presented in figure 4.6 below. The 
lower doses produced slight decreases in MAP which were neither dose-dependent nor 
statistically significant when compared to the control reading of 111.3mmHg ± 3.8. With 
the higher doses of EDD, dose-dependent and statistically significant increases in MAP 
occurred. A 31.5% increase in MAP occurred with the 3.0 mg/kg dose (from 111.3mmHg 
± 3.8 to 146.3mmHg ± 4.6), while a 37.7% increase occurred with the 4.0 mg/kg dose 
(from 111.3mmHg ± 3.8 to 153.2mmHg ± 8.2) and a 39.4% increase occurred with the 5.0 
mg/kg dose (from 111.3mmHg ± 3.8 to 155.1mmHg ± 5.7) (figure 4.6 and table 1).  
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Figure 4.6: Effect of (13S)-9α,13α-epoxylabda-6β(19),15(14)diol dilactone on mean 
arterial pressure.  
* Indicates statistical significance. 
 
 
 
 
 4.2.1.4 Effect on heart rate (HR) 
All doses of EDD administered produced dose-dependent decreases in HR (figure 4.7). The 
decreases produced ranged from a 10% decrease (from 368.4bpm ± 6.5 to 331.4bpm ± 6.1) 
with the 0.5 mg/kg dose to a 22.6% decrease (from 368.4bpm ± 6.5 to 285.2bpm ± 14.4) 
with the 5.0 mg/kg dose (table 1). All decreases were statistically significant when 
compared to the control reading of 368.4bpm ± 4.5. 
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Figure 4.7: Effect of (13S)-9α,13α-epoxylabda-6β(19),15(14)diol dilactone on heart 
rate.       
* indicates statistical significance. 
 
 
Table 1: Percentage change ± SEM (% ∆ ± SEM) for changes in SP, DP, MAP and 
HR after administration of EDD (0.5 mg/kg – 5.0 mg/kg). n=8. 
% ∆ ± SEM 
 
 
 
 
Dose (mg/kg) SP DP MAP HR 
0.5 
-2.0 ± 1.44 -3.1 ± 1.79 -2.3 ± 1.39 -10.0 ± 6.40 * 
1.0 
-3.7 ± 3.77 -6.3 ± 3.84 -4.3 ± 3.73 -12.9 ± 11.54 * 
2.0 
-3.4 ± 2.62 -6.5 ± 4.12 -4.0 ± 3.78 -15.3 ± 10.26 * 
3.0 29.7 ± 2.67 * 37.2 ± 4.88 * 31.5 ± 4.62 * -17.0 ± 19.41 * 
4.0 34.0 ± 7.81* 49.6 ± 9.18 * 37.7 ± 8.25 * -23.4 ± 17.18 * 
5.0 35.8 ± 5.1 * 51.0 ± 7.12 * 39.4 ± 5.71 * -22.6 ± 14.40 * 
* indicates statistical significance when compared to the control. 
 
4.2.2 Dose-response for the cardiovascular effects of standard drugs 
4.2.2.1 Effect on SP, DP and MAP 
Reserpine 
Figure 4.8 below shows the effect of reserpine administered in doses between 0.01 mg/kg 
and 1.00 mg/kg on blood pressure (BP). All doses administered induced significant dose-
dependent decreases in SP when compared to control (127.3mmHg ± 6.0). The lowest dose 
(0.01 mg/kg) produced the least decrease of 29.1% (from 127.3mmHg ± 6.0 to 90.3mmHg 
± 4.95), while the highest dose (1.00 mg/kg) produced the greatest decrease of 38.2% (from 
127.3mmHg ± 6.0 to 78.7mmHg ± 2.34) in SP. Reserpine also produced statistically 
significant decreases in DP with all the doses administered. The lowest dose induced the 
least decrease of 26.7% (from 82.3mmHg ± 9.4 to 60.3mmHg ± 1.42), while the greatest 
decrease in DP of 44.9% (from 82.3mmHg ± 9.4 to 45.3mmHg ± 2.5) was produced by the 
0.5 mg/kg dose. Dose-dependent decreases in MAP which were significant with all EDD 
doses administered occurred (figure 4.8).  
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Figure 4.8: Dose-response graph of the effect of reserpine on systolic pressure, 
diastolic pressure and mean arterial pressure.  
*Indicates statistical significance. 
 
Atenolol 
The effect of atenolol administered in the dose range of 0.5 mg/kg to 3.0 mg/kg is shown 
below in figure 4.9. Atenolol produced dose-dependent decreases in SP with the lowest 
dose producing the least decrease of 13.7% (from 131.9mmHg ± 1.0 to 113.9 mmHg ± 
1.03) and the highest dose producing the greatest decrease in SP of 47.1% (from 
131.9mmHg ± 1.0 to 69.8mmHg ± 4.01). All the doses produced statistically significant 
decreases in SP when compared to control (131.9mmHg ± 1.03). Significant dose-
dependent decreases in DP were also recorded with atenolol, ranging from a 10.9% 
decrease (from 73.7mmHg ± 0.4 to 65.7mmHg ± 0.3) with the lowest dose to a 32.7% 
decrease (from 73.7mmHg ± 0.4 to 49.6mmHg ± 4.8) with the highest dose (figure 4.9). 
 
 
 
 
Significant dose-dependent decreases in MAP also occurred with all doses of atenolol 
administered, ranging from a 13.1% decrease (from 112.5mmHg ± 2.6 to 97.8mmHg ± 2.5) 
with the lowest dose to a 44% decrease (from 112.5mmHg ± 2.6 to 63.0mmHg ± 1.5) with 
the highest dose (figure 4.9).   
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Figure 4.9: Dose-response graph of the effect of atenolol on systolic pressure, diastolic 
pressure and mean arterial pressure.  
* indicates statistical significance. 
 
Prazosin 
Figure 4.10 below illustrates the effect of prazosin (0.5 mg/kg – 10.0 mg/kg) on SP, DP 
and MAP. All doses administered induced significant dose-dependent decreases in SP 
when compared to the control (128.3mmHg ± 1.0). The lowest dose produced a 9.8% 
decrease (from 128.3mmHg ± 1.0 to 115.1mmHg ± 1.0), while the highest dose produced a 
28% decrease in SP (from 128.3mmHg ± 1.0 to 91.1mmHg ± 5.07). Significant dose-
 
 
 
 
dependent decreases in DP ranging from a 9.5% decrease (from 76.0mmHg ± 0.3 to 
65.9mmHg ± 0.3) to a 36.4% decrease (from 76.0mmHg ± 0.3 to 46.2mmHg ± 3.0) with 
the lowest and highest doses respectively also occurred. As expected statistically 
significant dose-dependent decreases in MAP also occurred with prazosin administration. 
A 9.6% decrease occurred (from 108.3mmHg ± 0.7 to 100.3mmHg ± 0.6) with the smallest 
dose and a 34.3% decrease occurred (from 108.3mmHg ± 0.7 to 76.2mmHg ± 4.3) with the 
largest dose when compared to the control (108.3mmHg ± 0. 7) (figure 4.10).     
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Figure 4.10: Dose-response graph of the effect of prazosin on systolic pressure, 
diastolic pressure and mean arterial pressure.  
* indicates statistical significance. 
 
Dobutamine  
 
 
 
 
The effect of dobutamine administered in the dose range of 30 µg/kg - 90 µg/kg on SP, DP 
and MAP is shown below in figure 4.11. Dobutamine produced dose-dependent increases 
in SP which were only significant with the 75 µg/kg and 90 µg/kg doses. The 75 µg/kg 
dose produced a 8.8% increase in SP (from 128.0mmHg ± 3.2 to 139.2mmHg ± 1.8) and 
the 90 µg/kg dose produced a 12.4% increase in SP (from 128.0mmHg ± 3.2 to 
143.9mmHg ± 4.8). Non-significant increases in DP were observed with the 30 µg/kg and 
45 µg/kg doses, but non-significant decreases in DP occurred with the administration of all 
other doses (figure 4.11). Non-significant dose-dependent increases in MAP were observed 
with the least increase of 1.8% (from 110.5mmHg ± 5.2 to 112.5mmHg ± 9.2) occurring 
with the lowest dose and the highest increase of 8.5% (from 110.5mmHg ± 5.2 to 
119.9mmHg ± 11.7) occurring with the greatest dose (figure 4.11).  
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Figure 4.11: Dose-response graph of the effect of dobutamine on systolic pressure, 
diastolic pressure and mean arterial pressure.  
* indicates statistical significance. 
 
 
 
 
 
 Verapamil 
Figure 4.12 illustrates the effect of verapamil (0.25 mg/kg to 5.0 mg/kg) on SP, DP and 
MAP. Verapamil produced dose-dependent decreases in SP, the least decrease of 8.6% 
(from 127.3mmHg ± 6.0 to 117.3 mmHg ± 3.9) and the greatest decrease of 44.1% (from 
127.3mmHg ± 6.0 to72.0mmHg ± 5.8) occurring with the lowest and highest doses 
respectively, significant when compared to control (127.3mmHg ± 6.0) only with doses 
above 0.5 mg/kg (figure 4.12). Dose-dependent decreases in DP were observed for all 
doses administered, with a 15.8% decrease (from 82.3mmHg ± 9.4 to 69.3mmHg ± 4.9) 
occurring with the lowest dose and a 59.8% decrease (from 82.3mmHg ± 9.4 to 33.1mmHg 
± 3.9) occurring with the highest dose. Apart from the lowest dose (0.25 mg/kg) decreases 
in DP were all statistically significant. Dose-dependent decreases in MAP were also 
observed for all doses administered, with a 9.8% decrease (from 112.3mmHg ± 3.5 to 
101.3mmHg ± 1.9) occurring with the lowest dose and a 47.4% decrease (from 
112.3mmHg ± 3.5 to 59.1mmHg ± 4.0) occurring with the highest dose. All decreases in 
MAP were statistically significant except with the 0.25 mg/kg dose (figure 4.12).  
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Figure 4.12: Dose-response graph of the effect of verapamil on systolic pressure, 
diastolic pressure and mean arterial pressure.  
* indicates statistical significance.                                               
 
4.2.2.3 Effect on heart rate (HR) 
Reserpine  
The effect of reserpine administered in the dose range of 0.01 mg/kg to 1.0 mg/kg on HR is 
shown below in figure 4.13. Dose-dependent decreases in HR occurred with all doses 
administered, ranging from a 8.7% decrease (from 368.7bpm ± 12.9 to 336.7bpm ± 7.2) 
with the lowest dose to a 27.8% decrease (from 368.7bpm ± 12.9 to 266bpm ± 2.95) with 
the highest dose. The decrease in HR was statistically significant for doses above 0.01 
mg/kg (figure 4.13). 
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Figure 4.13: Dose-response graph of the effect of reserpine on heart rate.                               
* indicates statistical significance. 
 
Atenolol  
Figure 4.14 illustrates the effect of the different doses of atenolol on HR. Atenolol 
produced significant dose-dependent decreases in HR for all doses administered ranging 
from a 16.5% decrease (from 364.4bpm ± 3.8 to 304.4bpm ± 3.7) with the lowest dose of 
0.5 mg/kg to a 52.6% decrease (from 364.4bpm ± 3.8 to 172.7bpm ± 4.6) with the highest 
dose (figure 4.14).  
0.5 1.0 1.5 2.0 3.0
1 6 0
1 8 5
2 1 0
2 3 5
2 6 0
2 8 5
3 1 0
3 3 5
3 6 0
C on tro l
D os e  (m g /k g )
He
ar
t r
at
e 
(bp
m
) * *
*
*
*
 
 
 
 
 
Figure 4.14: Dose-response graph of the effect of atenolol on heart rate.                                  
* indicates statistical significance. 
 
Prazosin  
The effect of prazosin administered in the dose range of 0.5 mg/kg to 10.0 mg/kg on HR is 
shown below in figure 4.15. Prazosin produced dose-dependent increases in HR with the 
lowest dose increasing HR by 3% (from 371.1bpm ± 5.3 to 375.1bpm ± 5.3) and the 
highest dose increasing HR by 20.3% (from 371.1bpm ± 5.3 to 438.0bpm ± 16.3). 
Statistically significant increases when compared to control (371.1bpm ± 5.3) only 
occurred with the 5.0 mg/kg and 10.0 mg/kg doses (figure 4.15). 
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Figure 4.15: Dose-response graph of the effect of prazosin on heart rate.                                    
* indicates statistical significance. 
 
 
Dobutamine  
 
 
 
 
Dobutamine administered in the dose range of 30 µg/kg to 90 µg/kg produced dose-
dependent increases in HR (figure 4.16). The lowest dose increased HR by 1.1% (from 
368.6bpm ± 6.3 to 372.6bpm ± 6.2) while the highest dose increased HR by 22.1% (from 
368.6bpm ± 6.3 to 450.1bpm ± 13.3). With the lowest dose, the increase in HR was non-
significant, while for all other doses statistically significant increases when compared to the 
control value of 368.6bpm ± 6.3 occurred (figure 4.16). 
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Figure 4.16: Dose-response graph of the effect of dobutamine on heart rate.                            
* indicates statistical significance. 
 
 
Verapamil  
Verapamil administered in the dose range of 0.25 mg/kg to 5.0 mg/kg produced dose-
dependent decreases in HR (figure 4.17). The lowest dose decreased HR by 5.6% (from 
368.3 ± 8.3 to 366.3bpm ± 3.3) while the highest dose decreased HR by 35.3% (from 369.3 
± 8.3 to 257.0bpm ± 4.0). With the lowest dose, the decrease in HR was non-significant, 
 
 
 
 
while for all other doses statistically significant decreases when compared to the control 
value of 368.3bpm ± 8.3 occurred (figure 4.17). 
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Figure 4.17: Dose-response graph of the effect of verapamil on heart rate.                               
* indicates statistical significance. 
 
 
4.2.3 Cardiovascular effects of EDD in the presence of standard drugs 
4.2.3.1 Systolic pressure (SP) 
Reserpine 
Figure 4.18 and tables 2 and 3 below illustrate the effect of EDD on SP in reserpinized 
animals. Reserpine pre-treatment decreased SP by 36.4% (from 127.3mmHg ± 6.0 control 
to 81.0mmHg ± 4.2). Administration of EDD afterwards led to significant dose-dependent 
increases in SP with the 0.5 mg/kg to 3.0 mg/kg doses of EDD. The greatest increase of 
50.6% (from 81.0mmHg ± 4.2 to 122.0mmHg ± 2.5) occurred with the lowest dose, while 
 
 
 
 
the least increase of 19.8% (from 81.0mmHg ± 4.2 to 105.9mmHg ± 7.0) occurred with the 
3.0 mg/kg dose. The 4.0 mg/kg and 5.0 mg/kg doses of EDD produced non-significant, 
dose-dependent decreases in SP (when compared to reserpine alone) (table 2).  
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Figure 4.18: Effect of EDD on systolic pressure in animals pre-treated with reserpine.           
* indicates statistical significance when compared to EDD administered alone. 
 
When compared with the SP values obtained with EDD administration in non-reserpinized 
animals, dose-dependent statistically significant decreases in SP occurred with the 
administration of EDD doses greater than 0.5 mg/kg in reserpinized animals (figure 4.18 
and table 3). The least decrease in SP of 5.9% (from 129.6mmHg ± 1.4 in non reserpinized 
animals to 122.0mmHg ± 2.5 in reserpinised animals) occurred with the 0.5 mg/kg dose 
which was non-significant, while the greatest decrease of 58.8% (from 183.4mmHg ± 5.2 
in non reserpinised animals to 75.6mmHg ± 3.2 in reserpinised animals) occurred with the 
largest dose (table 3). 
 
 
 
 
 
Table 2: Percentage change ± SEM (% ∆ ± SEM) for changes in SP, DP, MAP and 
HR after administration of EDD (0.5 mg/kg – 5.0 mg/kg) in animals pretreated with 
reserpine (0.5 mg/kg). n=8. 
% ∆ ± SEM 
EDD (mg/kg) SP DP MAP HR 
0.5 50.6 ± 1.23 * 65.3 ± 0.69 * 53.8 ± 1.32 * 12.7 ± 8.35  
1.0 42.5 ± 1.69 * 61.2 ± 2.54 * 46.6 ± 3.21 *   7.4 ± 3.45 
2.0 
  30.7 ± 0.58 * 50.4 ± 2.96 * 37.2 ± 1.67 *   1.5 ± 2.58 
3.0 19.8 ± 2.52 * 60.9 ± 1.35 * 28.7 ± 1.35 * -0.5 ± 4.21 
4.0 
-4.8 ± 1.98  55.0 ± 1.86 * 8.3 ± 1.86 * -7.3 ± 3.56 
5.0 
-6.7 ± 2.63  46.8 ± 2.98 * 8.9 ± 2.98 * -8.9 ± 4.25 
* indicates statistical significance when compared to reserpine (0.5 mg/kg). 
 
 
Table 3: Percentage change ± SEM (% ∆ ± SEM) for SP, DP, MAP and HR with EDD 
administration in reserpinised animals compared to EDD administration in non-
reserpinised animals. n=8. 
% ∆ ± SEM 
EDD (mg/kg) SP DP MAP HR 
0.5 
-5.0 ± 3.45 -3.3 ± 3.68 -5.3 ± 2.63 -5.3 ± 6.04 
1.0 
-12.5 ± 2.58 * -6.3 ± 1.23 -11.1 ± 2.54 * -5.9 ± 11.25 
2.0 
-19.0 ± 4.21 * -5.4 ± 1.69 -15.9 ± 2.96 * -7.1 ± 6.89 
3.0 
-45.0 ± 3.56 * -23.7 ± 0.58 * -40.4 ± 1.35 * -7.3 ± 12.31 
4.0 
-57.5 ± 4.25 * -30.6 ± 2.52 * -51.6 ± 1.86 * -8.6 ± 16.24 
5.0 
-58.8 ± 0.65 * -39.1 ± 1.98 * -52.6 ± 2.98 * -9.0 ± 9.34 
* indicates statistical significance when compared to EDD administered alone. 
 
 
 
 
 
Atenolol 
EDD was administered after administration of atenolol (2 mg/kg), and the effects on SP are 
shown in figure 4.19 and tables 4 and 5 below. Atenolol pre-treatment decreased SP by 
28.4% (from 131.9mmHg ± 1.0 to 94.5mmHg ± 3.8), and EDD administration afterwards 
produced increases in SP with all the doses. The increases were non-significant with the 0.5 
mg/kg – 2.0 mg/kg doses, but were significant with all other EDD doses when compared to 
atenolol (table 4).  
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Figure 4.19: Effect of EDD on systolic pressure in animals pre-treated with atenolol.                                                                    
* indicates statistical significance when compared to EDD administered alone. 
 
When compared with the SP values obtained with EDD administration in animals not pre-
treated, significant decreases in SP occurred for all EDD doses in animals pre-treated with 
atenolol (figure 4.19 and table 5). The least difference of 15.0% (from 123.0mmHg ± 2.6 in 
animals not pre-treated to 104.5mmHg ± 4.0 in pre-treated animals) occurred with the 2.0 
 
 
 
 
mg/kg dose while the greatest decrease in SP of 34.1% (from 166.0mmHg ± 2.6 in animals 
not pre-treated to 109.4mmHg ± 5.8 in pre-treated animals) occurred with the 3.0 mg/kg 
dose (table 5).  
 
Table 4: Percentage change ± SEM (% ∆ ± SEM) for changes in SP, DP, MAP and 
HR after administration of EDD (0.5 mg/kg – 5.0 mg/kg) in animals pre-treated with 
atenolol (2 mg/kg). n=8. 
% ∆ ± SEM 
EDD (mg/kg) SP DP MAP HR 
0.5 10.8 ± 2.56  16.0 ± 0.35 * 12.0 ± 4.45 * -2.4 ± 5.82  
1.0 10.4 ± 1.30  16.0 ± 1.70 * 11.7 ± 4.34 * -5.2 ± 5.35  
2.0 10.6 ± 3.70  15.5 ± 3.80 * 11.7 ± 4.38 * -10.8 ± 2.84 * 
3.0 15.8 ± 3.78 * 21.3 ± 4.13 * 17.0 ± 4.38 * -14.9 ± 5.38 * 
4.0 23.2 ± 4.68 * 25.1 ± 4.80 * 23.7 ± 2.49 * -19.2 ± 2.03 * 
5.0 26.9 ± 4.23 * 29.1 ± 3.83 * 27.4 ± 3.49 * -23.1 ± 4.24 * 
* indicates statistical significance when compared to atenolol (2.0 mg/kg). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5: Percentage change ± SEM (% ∆ ± SEM) for SP, DP, MAP and HR with EDD 
administration in animals pre-treated with atenolol compared to EDD administration 
in non pre-treated animals. n=8. 
% ∆ ± SEM 
EDD (mg/kg) SP DP MAP HR 
0.5 
-16.5 ± 1.92 * -13.9 ± 1.40 -15.9 ± 3.78 * -30.9 ± 3.58 * 
1.0 
-15.4 ± 4.45 * -11.0 ± 3.70 -14.3 ± 1.93 * -30.6 ± 3.75 * 
2.0 
-15.0 ± 4.34 * -11.0 ± 2.60 -14.1 ± 2.49 * -32.8 ± 2.45 * 
3.0 
-34.1 ± 4.38 * -36.4 ± 2.63 * -34.7 ± 4.02 * -34.6 ± 4.15 * 
4.0 
-32.1 ± 4.38 * -39.9 ± 7.80 * -34.1 ± 5.83 * -32.8 ± 6.03 * 
5.0 
-31.0 ± 2.49 * -38.5 ± 5.12 * -32.9 ± 5.72 * -36.6 ± 5.83 * 
* indicates statistical significance when compared to EDD administered alone. 
 
Prazosin 
EDD was administered after pre-treatment with prazosin (7.0 mg/kg), and the effects on SP 
are shown in figure 4.20 and tables 6 and 7 below. Prazosin pre-treatment decreased SP by 
25.4% (from 128.3mmHg ± 1.0 to 95.5mmHg ± 3.4), and with the administration of EDD 
slight non-significant non dose-dependent changes in SP occurred. Increases occurred with 
the 0.5 mg/kg and 2.0 mg/kg doses while decreases occurred with all other doses, but all 
were not significant when compared to the prazosin control (figure 4.20 and table 6).  
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Figure 4.20: Effect of EDD on systolic pressure in animals pre-treated with prazosin.                                
* indicates statistical significance when compared to EDD administered alone. 
 
When compared with the SP values obtained with EDD administration in animals not pre-
treated, significant decreases in SP occurred for all EDD doses in animals pre-treated with 
prazosin. The least decrease of 21.7% (from 123.7mmHg ± 2.6 in animals not pre-treated 
to 96.8mmHg ± 0.4 in pre-treated animals) occurred with the 2.0 mg/kg dose, while the 
greatest decrease of 45.3% (from 173.8mmHg ± 5.1 in animals not pre-treated to 
95.1mmHg ± 2.4 in pre-treated animals) occurred with the 5.0 mg/kg dose (table 7).  
 
 
 
Table 6: Percentage change ± SEM (% ∆ ± SEM) for changes in SP, DP, MAP and 
HR after administration of EDD (0.5 mg/kg – 5.0 mg/kg) in animals pre-treated with 
prazosin (7 mg/kg). n=8. 
 
 
 
 
% ∆ ± SEM 
EDD (mg/kg) SP DP MAP HR 
0.5 0.7 ± 1.43  -0.4 ± 1.77  1.03 ± 3.82  -11.9 ± 4.67 * 
1.0 
-0.2 ± 3.72  0.8 ± 2.35  0.0 ± 1.31  -12.5 ± 1.71 * 
2.0 1.4 ± 2.61  -2.4 ± 4.65  0.5 ± 3.70  -12.9 ± 3.82 * 
3.0 
-2.1 ± 2.63  -4.1 ± 4.10  -3.0 ± 3.80  -13.7 ± 4.12 * 
4.0 
-0.2 ± 2.28  4.4 ± 3.82  0.9 ± 0.40  -14.7 ± 4.80 * 
5.0 
-0.4 ± 0.20  1.4 ± 1.23  -0.0 ± 2.28  -18.2 ± 3.74 * 
* indicates statistical significance when compared to prazosin (7.0 mg/kg). 
 
 
Table 7: Percentage change ± SEM (% ∆ ± SEM) for SP, DP, MAP and HR with EDD 
administration in animals pre-treated with prazosin compared to EDD administration 
in non pre-treated animals. n=8. 
% ∆ ± SEM 
EDD (mg/kg) SP DP MAP HR 
0.5 
-23.3 ± 3.43 * -26.3 ± 2.57 * -23.7 ± 2.35 * 4.5 ± 2.25 * 
1.0 
-22.7 ± 4.25 * -22.9 ± 2.32 * -22.7 ± 4.65 * 7.2 ± 0.11 * 
2.0 
-21.7 ± 0.08 * -25.1 ± 0.20 * -22.5 ± 4.10 * 9.9 ± 0.27 * 
3.0 
-43.7 ± 0.43 * -49.9 ± 0.40 * -45.4 ± 3.80 * 11.0 ± 2.28 * 
4.0 
-44.4 ± 1.95 * -50.0 ± 2.28 * -45.8 ± 1.23 * 18.8 ± 0.20 * 
5.0 
-45.3 ± 0.06 * -51.9 ± 0.49 * -46.9 ± 3.55 * 12.8 ± 1.67 * 
* indicates statistical significance when compared to EDD administered alone. 
 
Dobutamine 
 
 
 
 
EDD was administered after pre-treatment with dobutamine (75 µg/kg), and the effects on 
SP are shown in figure 4.21 and tables 8 and 9 below. Dobutamine pre-treatment increased 
SP by 8.8% (from 128.0mmHg ± 3.2 to 139.2mmHg ± 1.8), and with the administration of 
EDD further dose-dependent increases in SP occurred, which were significant with the 
higher (3.0 mg/kg – 5.0 mg/kg) doses (figure 4.21 and table 8).  
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Figure 4.21: Effect of EDD on systolic pressure in animals pre-treated with 
dobutamine.                                                                                                                            
* indicates statistical significance when compared to EDD administered alone. 
 
When compared with the SP values obtained with EDD administration in animals not pre-
treated with dobutamine, significant increases in SP occurred with the 0.5 mg/kg, 1.0 
mg/kg, 2.0 mg/kg and 5.0 mg/kg doses in pre-treated animals (figure 4.21 and table 9). The 
least increase of 8% (from 173.8mmHg ± 5.1 in animals not pre-treated to 187.8mmHg ±  
3.0 in pre-treated animals) occurred with the 5.0 mg/kg dose, while the greatest increase of 
17.3% (from 123.0mmHg ± 2.6 in animals not pre-treated to 144.3mmHg ± 3.2 in pre-
 
 
 
 
treated animals) occurred with the 2.0 mg/kg dose. Non-significant decreases occurred with 
the 3.0 mg/kg and 4.0 mg/kg doses in animals pre-treated with dobutamine (table 9).  
 
Table 8: Percentage change ± SEM (% ∆ ± SEM) for changes in SP, DP, MAP and 
HR after administration of EDD (0.5 mg/kg – 5.0 mg/kg) in animals pre-treated with 
dobutamine (75 µg/kg). n=8. 
% ∆ ± SEM 
EDD (mg/kg) SP DP MAP HR 
0.5 1.6 ± 1.31  -0.8 ± 1.24 1.4 ± 1.41  -16.0 ± 3.80 * 
1.0 2.2 ± 1.51  4.8 ± 1.58 3.1 ± 3.71  -18.7 ± 1.34 * 
2.0 3.6 ± 2.59  -2.2 ± 2.81 2.7 ± 2.62  -19.5 ± 3.72 * 
3.0 16.1 ± 3.77 * 53.6 ± 3.24 * 24.4 ± 2.67 * -20.6 ± 3.78 * 
4.0 16.3 ± 1.87 * 69.8 ± 1.22 * 28.0 ± 7.87 * -20.8 ± 4.60 * 
5.0 34.9 ± 2.19 * 75.6 ± 3.13 * 43.9 ± 1.69 * -21.4 ± 8.21 * 
* indicates statistical significance when compared to dobutamine (75 µg/kg). 
 
 
 
 
 
 
 
 
Table 9: Percentage change ± SEM (% ∆ ± SEM) for SP, DP, MAP and HR with EDD 
administration in animals pre-treated with dobutamine compared to EDD 
administration in non pre-treated animals. n=8. 
 
 
 
 
% ∆ ± SEM 
EDD (mg/kg) SP DP MAP HR 
0.5 12.8 ± 1.24 * -1.5 ± 4.67 9.5 ± 1.31 * 11.2 ± 1.40 * 
1.0 15.5 ± 1.58 * 7.6 ± 1.70 13.7 ± 1.51 * 11.1 ± 3.71 * 
2.0 17.3 ± 2.81 * 0.7 ± 3.80 13.5 ± 2.59 * 13.2 ± 2.67 * 
3.0 
-2.6 ± 3.24 7.7 ± 4.10 -0.1 ± 3.77 13.9 ± 2.68 * 
4.0 
-5.6 ± 1.22 9.2 ± 4.88 -1.8 ± 1.87 23.1 ± 7.80 * 
5.0 8.0 ± 3.13 * 11.9 ± 3.83 * 9.0 ± 2.19 * 20.9 ± 5.10 * 
* indicates statistical significance when compared to EDD administered alone. 
 
Verapamil 
EDD was administered after pre-treatment with verapamil (4.0 mg/kg), and the effects on 
SP are shown in figure 4.22 and tables 10 and 11 below. Verapamil pre-treatment 
decreased SP by 41.1% (from 127.3mmHg ± 6.0 to 75.4mmHg ± 1.0), and with the 
administration of EDD a slight non-significant increase in SP occurred with the 0.5 mg/kg 
dose, while with all other doses significant dose-dependent increases in SP occurred (figure 
4.22 and table 10).  
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Figure 4.22: Effect of EDD on systolic pressure in animals pre-treated with verapamil.                             
* indicates statistical significance when compared to EDD administered alone. 
 
When compared to animals that received no pre-treatment, significant decreases in SP 
occurred for all EDD doses in animals pre-treated with verapamil. The least decrease of 
35.9% (from 125.4mmHg ± 1.4 in animals not pre-treated to 80.4mmHg ± 3.9 in pre-
treated animals) occurred with the lowest dose, while the greatest decrease of 62.4% (from 
173.8mmHg ± 5.1 in animals not pre-treated to 105.3mmHg ± 4.3 in pre-treated animals) 
occurred with the highest dose (figure 4.22 and table 11). 
 
 
 
 
 
 
 
 
 
Table 10: Percentage change ± SEM (% ∆ ± SEM) for changes in SP, DP, MAP and 
HR after administration of EDD (0.5 mg/kg – 5.0 mg/kg) in animals pre-treated with 
verapamil (4.0 mg/kg). n=8. 
% ∆ ± SEM 
EDD (mg/kg) SP DP MAP HR 
0.5 6.7 ± 1.70  16.3 ± 2.32 * 8.8 ± 4.93  5.7 ± 1.87 
1.0 12.5 ± 3.80 * 24.6 ± 2.01 * 15.2 ± 2.32 * 1.8 ± 3.04 
2.0 16.4 ± 4.10 * 26.4 ± 4.01 * 18.6 ± 2.10 * -1.6 ± 1.94 
3.0 23.0 ± 1.04 * 36.3 ± 2.28 * 25.9 ± 4.01 * -3.9 ± 7.92 
4.0 28.1 ± 3.94 * 48.4 ± 4.90 * 32.6 ± 2.28 * -5.2 ± 3.48 
5.0 39.7 ± 4.23 * 59.7 ± 1.68 * 44.1 ± 4.94 * -7.9 ± 2.34 
* indicates statistical significance when compared to verapamil (4.0 mg/kg). 
 
 
Table 11: Percentage change ± SEM (% ∆ ± SEM) for SP, DP, MAP and HR with 
EDD administration in animals pre-treated with verapamil compared to EDD 
administration in non pre-treated animals. n=8. 
% ∆ ± SEM 
EDD (mg/kg) SP DP MAP HR 
0.5 
-35.9 ± 1.40 * -33.9 ± 3.80 * -35.4 ± 1.87 * -14.8 ± 3.70 * 
1.0 
-39.3 ± 3.70 * -40.4 ± 1.30 * -39.6 ± 3.04 * -15.3 ± 2.60 * 
2.0 
-40.1 ± 2.60 * -42.0 ± 3.70 * -40.5 ± 1.94 * -15.7 ± 2.60 * 
3.0 
-56.2 ± 2.60 * -64.0 ± 3.40 * -58.1 ± 1.87 * -16.0 ± 7.28 * 
4.0 
-60.6 ± 3.48 * -71.1 ± 4.68 * -63.3 ± 3.04 * -10.3 ± 5.10 * 
5.0 
-62.4 ± 2.34 * -74.0 ± 1.49 * -65.4 ± 1.94 * -13.7 ± 4.93 * 
* indicates statistical significance when compared to EDD administered alone. 
 
 
 
 
 
4.2.3.2 Diastolic pressure (DP) 
Reserpine 
Figure 4.23 below illustrates the effect of EDD on diastolic pressure in reserpinised 
animals. Reserpine pre-treatment decreased DP by 44.9% (from 82.3mmHg ± 9.4 to 
45.3mmHg ± 2.5), and with the administration of EDD, significant dose-dependent 
increases in DP occurred (table 2). The greatest increase of 65.3% (from 45.3mmHg ± 2.5 
to 75.0mmHg ± 1.2) occurred with the lowest dose, while the least increase of 46.8% (from 
45.3mmHg ± 2.5 to 66.6mmHg ± 2.6) occurred with the highest dose (figure 4.23 and table 
2).  
When compared to non reserpinised animals, dose-dependent decreases in DP occurred for 
all EDD doses in reserpinised animals, but were significant with only the 3.0 mg/kg, 4.0 
mg/kg and 5.0 mg/kg doses. The least decrease of 3.3% (from 77.5mmHg ± 1.7 in non-
reserpinised to 75.0mmHg ± 1.2 in reserpinised animals) occurred with the lowest dose, 
while the greatest decrease of 39.1% (from 109.4mmHg ± 7.1 in non-reserpinised to 
66.6mmHg ± 2.6 in reserpinised animals) occurred with the highest dose (figure 4.23 and 
table 3). 
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Figure 4.23: Effect of EDD on diastolic pressure in animals pre-treated with 
reserpine.                                                                                                                                
* indicates statistical significance when compared to EDD administered alone. 
 
 
Atenolol 
The effects of EDD administered after pre-treatment with atenolol (2 mg/kg) on DP are 
shown in figure 4.24 below. Atenolol pre-treatment decreased DP by 23.9% (from 
73.7mmHg ± 0.4 to 56.1 mmHg ± 1.1), and with the administration of EDD increases in 
DP occurred with all the doses (table 4).  
When compared with the DP values obtained with EDD administration in animals not 
receiving atenolol pre-treatment, decreases in DP occurred for all EDD doses in pre-treated 
animals, but were statistically significant with the 3.0 mg/kg – 5.0 mg/kg doses (figure 4.24 
and table 5). The least decrease of 11% (from 73.1mmHg ± 3.8 in animals not pre-treated 
to 65.1mmHg ± 5.4 in pre-treated animals) occurred with the 1.0 mg/kg dose, while the 
 
 
 
 
greatest decrease of 39.9% (from 116.7mmHg ± 9.1 in animals not pre-treated to 
70.2mmHg ± 2.5 in pre-treated animals) occurred with the 4.0 mg/kg dose (table 5). 
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Figure 4.24: Effect of EDD on diastolic pressure in animals pre-treated with atenolol.                                  
* indicates statistical significance when compared to EDD administered alone. 
 
 
Prazosin 
EDD was administered after pre-treatment with prazosin (7.0 mg/kg), and the effects on 
DP are shown in figure 4.25 below. Prazosin pre-treatment decreased DP by 28.3% (from 
76.0mmHg ± 0.3 to 55.9mmHg ± 2.6), and with the administration of EDD, slight non-
significant non dose-dependent changes in DP occurred. Increases occurred with the 1.0 
mg/kg, 4.0 mg/kg and 5.0 mg/kg doses while decreases occurred with all other doses, but 
all were not significant when compared to the prazosin control (figure 4.25 and table 6).  
 
 
 
 
When compared with the DP values obtained with EDD administration in animals not 
receiving prazosin pre-treatment, significant decreases in DP occurred for all EDD doses in 
animals pre-treated with prazosin. The least decrease of 22.9% (from 73.1mmHg ± 3.8 in 
animals not pre-treated to 82.3mmHg ± 0.1 in pre-treated animals) occurred with the 1.0 
mg/kg dose, while the greatest decrease of 51.9% (from 117.8mmHg ± 7.1 in animals not 
pre-treated to 56.7mmHg ± 0.2 in pre-treated animals) occurred with the 5.0 mg/kg dose 
(figure 4.25 and table 7).  
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Figure 4.25: Effect of EDD on diastolic pressure in animals pre-treated with prazosin.                                 
* indicates statistical significance when compared to EDD administered alone. 
 
 
Dobutamine 
EDD was administered after pre-treatment with dobutamine (75 µg/kg), and the effects on 
DP are shown in figure 4.26 below. Dobutamine pre-treatment decreased DP by 5.1% 
 
 
 
 
(from 79.0mmHg ± 3.3 to 75.0mmHg ± 1.3), and with the administration of EDD increases 
in DP occurred with the 1.0 mg/kg, 3.0 mg/kg, 4.0 mg/kg and 5.0 mg/kg, which were 
statistically significant with the higher (3.0 mg/kg – 5.0 mg/kg) doses. Non significant 
decreases in DP occurred with the 0.5 mg/kg and 2.0 mg/kg doses (figure 4.26 and table 8).  
When compared with the DP values obtained with EDD administration in animals not 
receiving dobutamine pre-treatment, increases in DP occurred with the 1.0 mg/kg - 5.0 
mg/kg doses in animals pre-treated with dobutamine. A 0.7% increase (from 72.9mmHg ± 
4.1 in animals not pre-treated to 73.4mmHg ± 3.8 in pre-treated animals) occurred with the 
2.0 mg/kg dose which was the least increase. Statistically significant increases occurred 
only with the 5.0 mg/kg dose with an 11.9% increase (from 117.8mmHg ± 7.1 in animals 
not pre-treated to 131.8mmHg ± 1.7 in pre-treated animals). A slight non-significant 
decrease occurred with the 0.5 mg/kg dose (figure 4.26 and table 9).  
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Figure 4.26: Effect of EDD on diastolic pressure in animals pre-treated with 
dobutamine.                                                                                                                            
* indicates statistical significance when compared to EDD administered alone. 
 
 
 
 
Verapamil 
EDD was administered after pre-treatment with verapamil (4.0 mg/kg), and the effects on 
DP are shown in figure 4.27 below. Verapamil pre-treatment decreased DP by 44.9% (from 
78.0mmHg ± 4.7 to 43.0mmHg ± 4.9), and with the administration of EDD, dose-
dependent increases occurred with all doses (table 10).  
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Figure 4.27: Effect of EDD on diastolic pressure in animals pre-treated with 
verapamil.                                                                                                                               
* indicates statistical significance when compared to EDD administered alone. 
 
When compared with the DP values obtained with EDD administration in animals that 
received no verapamil pre-treatment, significant dose-dependent decreases in DP occurred 
for all EDD doses in animals pre-treated with verapamil. The least decrease of 33.9% (from 
75.6mmHg ± 1.7 in animals not pre-treated to 50.0mmHg ± 2.3 in pre-treated animals) 
occurred with the smallest dose, while the greatest decrease of 74% (from 117.8mmHg ± 
 
 
 
 
7.1 in animals not pre-treated to 68.6mmHg ± 1.7 in pre-treated animals) occurred with the 
5.0 mg/kg dose (table 11). 
 
4.2.3.3 Mean arterial pressure (MAP) 
Reserpine 
Figure 4.28 below illustrates the effect of EDD on MAP in reserpinized animals. Reserpine 
pre-treatment decreased MAP by 38.5% (from 112.3mmHg ± 3.5 to 69.1mmHg ± 5.3), and 
with the administration of EDD dose-dependent increases in MAP occurred with all doses 
of EDD. The highest increase of 53.8% (from 69.1mmHg ± 5.3 to 106.3mmHg ± 0.7) 
occurred with the smallest dose, while the smallest increase of 8.3% (from 69.1mmHg ± 
5.3 to 74.8mmHg ± 1.4) occurred with the 4.0 mg/kg dose (figure 4.28 and table 2).  
When compared with the MAP values obtained with EDD administration in non-
reserpinised animals, dose-dependent decreases in MAP occurred in reserpinised animals 
which were significant for all doses above 0.5 mg/kg (figure 4.28 and table 3).   
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Figure 4.28: Effect of EDD on mean arterial pressure in animals pre-treated with 
reserpine.                                                                                                                                
* indicates statistical significance when compared to EDD administered alone. 
 
Atenolol 
The effects of EDD administered after pre-treatment with atenolol (2 mg/kg) on MAP are 
illustrated below in figure 4.29. Atenolol pre-treatment decreased MAP by 23.4% (from 
112.5mmHg ± 2.6 to 81.7mmHg ± 1.9), and with the administration of EDD significant 
dose-dependent increases in MAP occurred (table 4).  
When compared with the MAP values obtained with EDD administration in animals not 
pre-treated with atenolol, all doses produced significantly lower increases to MAP (table 
5). The least difference of 14.1% (from 106.3mmHg ± 3.7 in animals not pre-treated to 
91.3mmHg ± 4.4 in pre-treated animals) occurred with the 2.0 mg/kg dose, while the 
greatest difference of 34.7% (from 146.3mmHg ± 4.6 in animals not pre-treated to 
 
 
 
 
68.0mmHg ± 5.4 in pre-treated animals) occurred with the 3.0 mg/kg dose (figure 4.29 and 
table 5). 
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Figure 4.29: Effect of EDD on mean arterial pressure in animals pre-treated with 
atenolol.                                                                                                                                   
* indicates statistical significance when compared to EDD administered alone. 
 
Prazosin 
EDD was administered after pre-treatment with prazosin (7.0 mg/kg), and the effects on 
MAP are shown in figure 4.30 below. Prazosin pre-treatment decreased MAP by 23.2% 
(from 108.3mmHg ± 0.7 to 83.2mmHg ± 4.5), and with the administration of EDD slight 
non-significant non dose-dependent changes in MAP occurred. Increases occurred with the 
0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg and 4.0 mg/kg doses while decreases occurred with all 
other doses, but all were not significant when compared to the prazosin control (table 6).  
When compared with the MAP values obtained with EDD administration in animals not 
receiving prazosin pre-treatment, significant decreases in MAP occurred for all EDD doses 
 
 
 
 
in animals pre-treated with prazosin (table 7). The least difference of 22.5% (from 
106.8mmHg ± 3.7 in animals not pre-treated to 82.8mmHg ± 0.3 in pre-treated animals) 
occurred with the 2.0 mg/kg dose, while the greatest difference of 46.9% (from 
155.1mmHg ± 5.7 in animals not pre-treated to 82.3mmHg ± 1.7 in pre-treated animals) 
occurred with the 5.0 mg/kg dose (figure 4.30 and table 7). 
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Figure 4.30: Effect of EDD on mean arterial pressure in animals pre-treated with 
prazosin. * indicates statistical significance when compared to EDD administered 
alone. 
 
Dobutamine 
EDD was administered after pre-treatment with dobutamine (75 µg/kg), and the effects on 
MAP are shown in figure 4.31 below. Dobutamine pre-treatment increased MAP by 6.3% 
(from 110.5mmHg ± 5.2 to 117.5mmHg ± 1.2), and with the administration of EDD further 
dose-dependent increases in MAP occurred which were significant with the 3.0 mg/kg, 4.0 
mg/kg and 5.0 mg/kg doses (table 8). When compared with the MAP values obtained with 
 
 
 
 
EDD administration in animals not receiving dobutamine pre-treatment, statistically 
significant increases in MAP occurred with the 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg and 5.0 
mg/kg doses, while slight non-significant decreases occurred with the 3.0 mg/kg and 4.0 
mg/kg doses in pre-treated animals (figure 4.31 and table 9).  
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Figure 4.31: Effect of EDD on mean arterial pressure in animals pre-treated with 
dobutamine.                                                                                                                            
* indicates statistical significance when compared to EDD administered alone. 
 
 
Verapamil 
EDD was administered after pre-treatment with verapamil (4.0 mg/kg), and the effects on 
MAP are shown in figure 4.32 below. Verapamil pre-treatment decreased MAP by 37.6% 
(from 103.4mmHg ± 3.8 to 64.6mmHg ± 1.9), and with the administration of EDD dose-
dependent increases in MAP occurred which were statistically significant with doses above 
0.5 mg/kg (table 10).  
 
 
 
 
When compared with the MAP values obtained with EDD administration in animals not 
pre-treated with verapamil, significant decreases in MAP occurred for all EDD doses in 
animals pre-treated with verapamil (table 11). The least difference of 35.4% (from 
108.8mmHg ± 1.3 in animals not pre-treated to 70.3mmHg ± 3.0 in pre-treated animals) 
occurred with the lowest dose, while the greatest difference of 65.4% (from 155.1mmHg ± 
5.7 in animals not pre-treated to 93.1mmHg ± 5.2 in pre-treated animals) occurred with the 
5.0 mg/kg dose (figure 4.32 and table 11). 
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Figure 4.32: Effect of EDD on mean arterial pressure in animals pre-treated with 
verapamil.                                                                                                                               
* indicates statistical significance when compared to EDD administered alone. 
 
4.2.3.4 Heart rate (HR) 
Reserpine 
 
 
 
 
Figure 4.33 below illustrates the effect of EDD on HR in reserpinized animals. Reserpine 
pre-treatment decreased HR by 21.2% (from 368.7bpm ± 12.9 to 290.7bpm ± 6.0), and 
with the administration of EDD increases in HR occurred with the 0.5 mg/kg – 2.0 mg/kg 
doses, while dose-dependent decreases occurred with the 3.0 mg/kg – 5.0 mg/kg doses 
(table 2). The highest increase of 12.7% (from 290.7bpm ± 6.0 to 327.5bpm ± 11.3) 
occurred with the smallest dose, while the smallest increase of 1.5% (from 290.7bpm ± 6.0 
to 295.0bpm ± 12.3) occurred with the 2.0 mg/kg dose (figure 4.33 and table 2).  
When compared with the HR values obtained with EDD administration in non-reserpinised 
animals, non-significant decreases in HR occurred with all doses administered in 
reserpinised animals (figure 4.33 and table 3).  
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Figure 4.33: Effect of EDD on heart rate in animals pre-treated with reserpine.                    
* indicates statistical significance when compared to EDD administered alone. 
 
 
 
 
 Atenolol 
EDD was administered after pre-treatment with atenolol (2 mg/kg), and the effects on HR 
are shown in figure 4.34 below. Atenolol pre-treatment decreased HR by 36.3% (from 
364.4bpm ± 3.8 to 234.9bpm ± 3.6), and with the administration of EDD further dose-
dependent decreases in HR occurred with all the doses (statistically significant with the 2.0 
mg/kg – 5.0 mg/kg doses) (table 4). 
When compared with the HR values obtained with EDD administration in animals not pre-
treated with atenolol, statistically significant decreases in HR occurred with all doses 
administered in pre-treated animals (table 5). The least difference of 30.6% (from 321bpm 
± 11.0 in animals not pre-treated to 222.7bpm ± 2.5 in pre-treated animals) occurred with 
the 1.0 mg/kg dose, while the greatest difference of 36.6% (from 285.2bpm ± 14.4 in 
animals not pre-treated to 180.7bpm ± 4.7 in pre-treated animals) occurred with the 5.0 
mg/kg dose (figure 4.34 and table 5). 
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Figure 4.34: Effect of EDD on heart rate in animals pre-treated with atenolol.                                
* indicates statistical significance when compared to EDD administered alone. 
 
Prazosin 
EDD was administered after pre-treatment with prazosin (7.0 mg/kg), and the effects on 
HR are shown in figure 4.35 below. Prazosin pre-treatment increased HR by 6.7% (from 
368.4bpm ± 6.5 to 393.2bpm ± 3.4), and with the administration of EDD significant dose-
dependent decreases in HR occurred (table 6).  
When compared with the HR values obtained with EDD administration in animals that 
received no prazosin pre-treatment, significant increases in HR occurred for all EDD doses 
in animals pre-treated with prazosin (table 7). The least difference of 4.5% (from 331.4bpm 
± 6.4 in animals not pre-treated to 346.4bpm ± 4.7 in pre-treated animals) occurred with the 
lowest dose, while the greatest difference of 18.8% (from 282.3bpm ± 17.1 in animals not 
 
 
 
 
pre-treated to 335.4 ± 3.6 in pre-treated animals) occurred with the 4.0 mg/kg dose (figure 
4.35 and table 7).  
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Figure 4.35: Effect of EDD on heart rate in animals pre-treated with prazosin.                               
* indicates statistical significance when compared to EDD administered alone. 
 
 
Dobutamine 
EDD was administered after pre-treatment with dobutamine (75 µg/kg), and the effects on 
HR are shown in figure 4.36 below. Dobutamine pre-treatment increased HR by 19.1% 
(from 368.6bpm ± 6.3 to 438.6bpm ± 12.6), and with the administration of EDD significant 
dose-dependent decreases in HR occurred (table 8).  
When compared with the HR values obtained with EDD administration in animals not pre-
treated with dobutamine, statistically significant increases in HR occurred in pre-treated 
animals with all doses administered (table 9). The least difference of 11.1% (from 
 
 
 
 
321.0bpm ± 11.0 in animals not pre-treated to 356.6bpm ± 2.8 in pre-treated animals) 
occurred with the 1.0 mg/kg dose, while the greatest difference of 23.1% (from 282.3bpm 
± 17.1 in animals not pre-treated to 347.5bpm ± 1.6 in pre-treated animals) occurred with 
the 4.0 mg/kg dose (figure 4.36 and table 9). 
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Figure 4.36: Effect of EDD on heart rate in animals pre-treated with dobutamine.                         
* indicates statistical significance when compared to EDD administered alone. 
 
 
Verapamil 
EDD was administered after pre-treatment with verapamil (4.0 mg/kg), and the effects on 
HR are shown in figure 4.37 below. Verapamil pre-treatment decreased HR by 27.5% 
(from 368.4bpm ± 6.5 to 267.2bpm ± 4.0), and with the administration of EDD dose-
dependent increases occurred with the 0.5 mg/kg and 1.0 mg/kg doses, while dose-
 
 
 
 
dependent decreases occurred with the other doses (2.0 mg/kg – 5.0 mg/kg) (figure 4.37). 
All changes to HR were however non-statistically significant (table 10).  
When compared with the HR values obtained with EDD administration in animals not pre-
treated with verapamil, significant decreases in HR occurred for all EDD doses in animals 
pre-treated with verapamil (table 11). The least difference of 10.3% (from 282.3bpm ± 17.1 
in animals not pre-treated to 253.3bpm ± 2.4 in pre-treated animals) occurred with the 4.0 
mg/kg dose, while the greatest difference of 16% (from 305.8bpm ± 19.4 in animals not 
pre-treated to 256.8bpm ± 1.1 in pre-treated animals) occurred with the 3.0 mg/kg dose 
(figure 4.37 and table 11). 
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Figure 4.37: Effect of EDD on heart rate in animals pre-treated with verapamil.                            
* indicates statistical significance when compared to EDD administered alone. 
 
CHAPTER FIVE 
Discussion  
 
 
 
 
 5.1 Structure elucidation 
Fractionation of the organic extracts of the leaves of L. leonurus yielded colourless needles 
of a new diterpenoid compound named (13S)-9α, 13α-epoxylabda-6β(19),15(14)diol 
dilactone (EDD).  
Diastereotopic protons in the δ 1 to 2.5 ppm region and the doublet of doublets at δ 4.70 
ppm region of the 1H NMR spectrum of EDD indicated that the new molecule was likely to 
be a diterpenoid with similarities to those previously isolated from the plant (see 
appendixes II-IX) (Rivett, 1964; Kaplan and Rivett 1968; Habtemariam et al., 1994; 
McKenzie et al., 2006; Agnihotri et al., 2009). The 13C NMR spectrum of the compound 
indicated the presence of 20 unique carbon atoms and the DEPT spectrum indicated the 
presence of three CH3, eight CH2 and three CH groups. The distinctive chemical shifts of 
two of the remaining six quaternary carbons at δ 83.6 and 93.5 ppm indicated the likely 
presence of two-spiro fused five-membered rings. Chemical shifts at δ 183.8 and 171.4 
ppm indicated the presence of two carbonyl moieties (see appendixes X-XII). 
 
The spectral data presented above suggested a number of similarities with another 
diterpenoid simply known as compound X, that had previously been isolated from L. 
leonurus and this assisted in the deduction of the structure of this new diterpenoid (Kaplan 
and Rivett 1968). From the HSQC, HMBC and COSY NMR spectra the presence of ethano 
carbons at C-15 and C-16 in EDD (coupling seen in the 1H and COSY NMR spectra in 
appendixes II - IX and XII – XVI respectively) as opposed to compound X which has two 
isolated CH2 groups at C-14 and C-16, helped confirm that EDD and compound X are 
 
 
 
 
positional isomers of one another (see figure 5.1). The main structural difference between 
the two compounds is that the lactone carbonyl group in EDD is at the C-14 position while 
in compound X, the lactone carbonyl group is at the C-15 position (figure 5.1).   
 
 
Figure 5.1: Positional isomerism between EDD (1) and compound X (2). 
 
The IR spectra of EDD showed absorptions at: 2909 cm
-1
 and 1374 cm
-1 
due to the 
saturated C - H bond; 1770 cm
-1
and 1100 cm
-1
due to double and single bond character of 
the ester C = O bond; 1462 cm
-1
 due to the saturated C - H stretching frequencies; 1196  
cm
-1
 due to O – C = O bond stretching and 911 cm
-1
due to C - O cyclic bonds (see 
appendix I). The high-resolution electron impact mass spectrum (HREIMS) indicated a 
[M+H]+ ion at m/z 349.2009, which correlates with the molecular formula C20H29O5 
(calculated for C20H29O5 at 349.2015), and X-ray crystallography confirmed the structure 
of the compound (see figure 4.2 and appendix XXXVI). An extensive search of the 
 
 
 
 
literature and databases of chemical structures indicated that this is the first time the 
diterpenoid (13S)-9α, 13α-epoxylabda-6β(19),15(14)diol dilactone has been isolated from 
L. leonurus or any other plant.  
 
Despite the abundance of terpenoids, especially the diterpenoid lactones in the Leonotis 
species, it is surprisingly rewarding to our group that this is the first time this compound 
has been isolated from the plant. Geographical differences in the constituents of L. 
leonurus have been reported by some researchers as a possible reason for the isolation of 
compounds which had not been previously isolated from the plant (Laonigro et al., 1979; 
McKenzie et al., 2006). This could explain the isolation of the novel compound EDD from 
the plant, as leonurun, another novel compound isolated from L. leonurus harvested from 
the same geographical location as the plants used in this study, has been reported by 
Mckenzie and co-workers (2006). As noted earlier, most of the compounds so far isolated 
from the plant have been diterpenoids with closely related structures (see figure 2.2). The 
relative stereochemistry of EDD is consistent with that of other diterpenoids so far isolated 
from L. leonurus as evidenced from the scalar couplings measured in the 1H NMR 
spectrum and also from correlations observed in the 2D NOESY spectrum collected (see 
Figure 4. 3) (Rivett, 1964; Kaplan and Rivett 1968; Laonigro et al., 1979; Kruger and 
Rivett 1988; McKenzie et al., 2006; Obikeze et al., 2008).  
 
5.2 In vivo cardiovascular effects of EDD 
The diterpenoid (13S)-9α, 13α-epoxylabda-6β(19),15(14)diol dilactone (EDD) isolated 
from the methanol extracts of the leaves of L. leonurus was administered intravenously to 
 
 
 
 
anaesthetized normotensive male Wistar rats in order to evaluate its cardiovascular effect. 
The lower doses (0.5 mg/kg, 1.0 mg/kg and 2.0 mg/kg) of EDD seemed to have little or no 
effect on blood pressure (slight non-significant decreases in SP, DP and MAP) (see figures 
4.4 – 4.6 and table 1), while the administration of the higher doses (3.0 mg/kg, 4.0 mg/kg 
and 5.0 mg/kg) of EDD induced dose-dependent statistically significant increases in BP 
(see figures 4.4 – 4.6 and table 1). The decreases in BP with the lower doses of EDD 
though non-significant, were similar to the effects of the aqueous extract as reported by 
Ojewole (2003). The increases in BP observed with the higher doses on the other hand 
were similar to those reported by Obikeze (2005) using the crude aqueous extract of L. 
leonurus leaves in the same animal model and also using a fraction of the methanol extract 
in the isolated perfused rat heart model. The observed dose-dependent effects of EDD on 
BP were similar to those that had been previously reported with other compounds (Church 
and Hodgson 2000). All doses of EDD administered also induced significant dose-
dependent decreases in HR, an effect quite similar to that observed with other diterpenoids 
(see figure 4.7 and table 1) (Somova et al., 2001; Silva et al., 2005). The results seem to 
suggest that EDD exhibits a dual effect in the cardiovascular system of the rats: a negative 
chronotropic effect and a vasoconstrictive effect. None of the diterpenoids so far isolated 
from L. leonurus have been assayed for possible cardiovascular activity, but diterpenoids 
isolated from other plants have been reported to exhibit various effects on the 
cardiovascular system such as vasorelaxation, bradycardia, tachycardia and diuresis 
(Somova et al., 2001; Guerrero et al., 2004; Silva et al., 2005; de Oliveira et al., 2006; 
Lahlou et al., 2007). 
 
 
 
 
The decreases in SP, DP and MAP observed with the lower EDD doses though only slight 
and non-significant were similar to the effects reported by Mugabo et al (2002)and 
Ojewole (2003) using the crude aqueous extracts of L. leonurus in anaesthetized 
normotensive rats. This effect was also similar to the vasorelaxant effects that have been 
reported with other diterpenoids isolated from plants (Dubey et al., 1981; Somova et al., 
2001; Oliveira et al., 2003; Guerrero et al., 2004; Ambrosio et al., 2006; Lahlou et al., 
2007). Vasoconstrictive effects similar to those observed with the higher EDD doses have 
also been reported with other plant extracts such as pilosidine isolated from Curculigo 
pilosa, but are yet to be reported with diterpenoids (Kwan et al., 1999; Cometa et al., 2001; 
Chen et al., 2004). The dose dependent decreases in HR produced by all EDD doses on the 
other hand were similar to the effects of the aqueous extract of L. leonurus as reported by 
both Obikeze (2005) and Ojewole (2003) in anaesthetized normotensive rats, and also with 
some diterpenoids isolated from other plants as reported by Somova and co-workers (2001) 
and Silva and co-workers (2005). Interestingly, the opposite effect (a positive chronotropic 
effect) was reported by Mugabo and co-workers (2002) with the crude aqueous extract of 
L. leonurus in Langendorff perfused isolated rat hearts and by Obikeze (2005) with a 
fraction of the methanol extract of the leaves of L. leonurus administered to anaesthetized 
normotensive rats.  
 
Intricate relationships exist between the various components making up the cardiovascular 
system as seen in the equations below:   
        Blood Pressure (BP) = Cardiac Output (CO) x Peripheral Vascular Resistance (PVR) 
                                                    and 
 
 
 
 
        Cardiac Output (CO) = Heart Rate (HR) x Stroke Volume (SV) 
The interplay of the various components of the above equations would influence the 
resultant cardiovascular effects of any administered compounds. A direct relationship 
exists between BP and HR, with an increase in HR resulting in an increase in BP and vice 
versa. With EDD administration, especially with the higher doses, decreases in HR 
coincided with increases in BP, suggesting that the compound may have a dual effect on 
the cardiovascular system: acting independently on the heart to produce a reduction in HR 
and at the same time increasing PVR to produce an increase in BP. Methoxamine (a 
selective α-adrenoceptor agonist) produces an increase in BP via vasoconstriction that is 
accompanied by bradycardia due to the activation of the baroreceptor reflex, and this effect 
is similar to that observed with the higher doses of EDD (Hoffman, 1998a). Activation of 
the baroreceptor reflex may be responsible for the decrease in HR that is seen 
accompanying the increase in BP with the higher EDD doses, but this does not however 
explain the decrease in HR that accompanied the slight decrease in BP observed with the 
lower EDD doses. Biphasic effects similar to the one that was observed with the 
administration of EDD have also been reported with other diterpenoids isolated from other 
plants, but these have mainly been in the form of tachycardia accompanying a hypotensive 
effect (Aceret et al., 1996; de Oliviera et al 2006; Lahlou et al., 2007). The decrease in BP 
at the lower doses may however be due to a vasodilatory effect, which has been reported 
with many other diterpenes, but the significant increases in BP that occurred with the 
higher EDD doses make a vasodilatory effect highly unlikely (Somova et al., 2001; Silva et 
al., 2005). The decreases in BP with the lower doses may be the result of a greater negative 
chronotropic effect overcoming the weaker vasoconstrictor effect elicited at these doses. 
 
 
 
 
The decrease in HR observed with EDD administration is probably not the result of the 
activation of the baroreceptor reflex, but rather the result of a direct negative chronotropic 
effect on the heart by the compound. Thus, if baroreceptor reflex activation is not entirely 
responsible for the negative chronotropic effect of the lower doses of EDD, and BP is 
elevated while HR is decreased at the higher doses of EDD, then it is probable that EDD 
exhibits a dual effect on the cardiovascular system viz., an increase in BP due to a 
vasoconstrictor effect and a decrease in HR due to a negative chronotropic effect.  
Increases in BP could occur either through a direct vasoconstrictor effect or an indirect 
vasoconstrictor effect (Ruffolo and Hieble 1995; Hoffman, 1998a). A direct vasoconstrictor 
effect is mediated by an agonistic effect on α1 receptors found in contractile tissue of the 
arteries, while an indirect vasoconstrictor effect is mediated via the release of 
catecholamines into the synaptic space (Ruffolo and Hieble 1994; Hoffman, 1998a). 
Reserpine depletes vascular stores of catecholamines and the pre-treatment of the animals 
with this drug would decrease the vasoconstrictive effect of EDD, if this effect was 
mediated via the release of catecholamines at the synapse (Chen and Chan 1989; Consolini 
and Sarrubbio 2002). EDD administration in animals pre-treated with reserpine led to dose-
dependent decreases in BP when compared to the EDD effect in non-reserpinized animals 
(see figures 4.18, 4.23, 4.28 and table 3). The decreases observed were statistically 
significant at the higher doses administered and BP values were even lower than the values 
in the control group. The administration of reserpine led to the elimination of the 
vasoconstrictive effect produced by EDD, indicating that EDD may produce its 
vasoconstrictive effect via the release of catecholamines (Korsziak and Story 1994; 
Consolini and Sarubbio 2002). No significant changes in HR occurred in reserpinized 
 
 
 
 
animals compared to their non-reserpinized counterparts and this indicates that EDD does 
not produce its negative chronotropic effect by preventing the release of catecholamines. 
The results from reserpinized animals gives a strong indication that EDD has a vasodilatory 
effect, and the possibility of this being the result of an agonistic effect on α1 receptors is 
further explored. The administration of EDD in animals pre-treated with prazosin, an α1 
adrenoceptor blocker, produced no significant changes in BP. Compared to non pre-treated 
animals BP values in pre-treated animals were however significantly reduced (see figure 
4.20, 4.25, 4.30 and table 7). The fact that pre-treatment with prazosin, an α1 adrenoceptor 
blocker, abolished the vasoconstrictive effect of EDD suggests that its effect on BP is 
mediated by α1 receptors (Frew et al., 1994). HR values were significantly higher in 
animals pre-treated with prazosin compared to those without prazosin pre-treatment as a 
result of reflex tachycardia occurring with prazosin administration (see figure 4.35, table 7) 
(Shah and Yadav 2008). The results obtained in animals pre-treated with reserpine and 
prazosin suggests that EDD produces an indirect vasoconstrictive effect in the animals via 
the release of catecholamines. This indirect vasoconstrictive mechanism has been reported 
as the mechanism for the effect of 1-α-naphthylmethyl-6,7-dihydroxy-1,2,3,4-
tetrahydroisoquinoline and the crude venom gland extract of Steatoda capensis on BP 
(Korszniak and Story 1994; Lee et al., 1994).  
EDD produced a negative chronotropic effect on the heart that could be due to β1 
adrenoceptor blockade, Ca2+ channel blockade, or Na+/K+ pump blockade. Various 
diterpenoids have been reported to affect the heart via these mechanisms (Toya et al., 1998; 
Silva et al., 2005; De Oliveira et al., 2006). Atenolol produces a negative chronotropic 
effect via β1 adrenoceptor blockade and administration with another negative chronotropic 
 
 
 
 
agent should produce an additive effect (Pearson et al., 1989). EDD administration in 
animals pre-treated with atenolol led to further dose dependent decreases in HR (see figure 
4.34 and table 5). The results however are not conclusive on the mechanism of action of 
EDD as the additive effect on HR could also be due to Ca2+ channel and/or Na+/K+ pump 
blockade (Summers and McMartin 1993). The results however give a clear indication that 
EDD does have a negative chronotropic effect on the heart. Interestingly there were 
increases in BP with the administration of EDD in animals pre-treated with atenolol, but 
these values were significantly lower than the values obtained with the administration of 
EDD in non pre-treated animals. This once more suggests a dual effect for EDD since 
increases in BP occurred even in the presence of the combined negative chronotropic 
effects of atenolol and EDD. Animals were pre-treated with dobutamine, a β1 adrenoceptor 
agonist, prior to the administration of EDD to determine if the negative chronotropic effect 
of EDD was the result of β1 adrenoceptor blockade. Administration of a β1 adrenoceptor 
agonist leads to an increase in HR, an effect that would be reversed by a β1 adrenoceptor 
antagonist administered afterwards (Hoffman, 1998b). Dobutamine as expected produced 
an increase in HR in the animals and the administration of EDD in those animals pre-
treated with dobutamine lead to significant decreases in HR (see figure 4.36, table 9). The 
decrease in HR with the administration of EDD in animals pre-treated with dobutamine 
was similar to the effect reported with atenolol and CGP 20712A, both β1 adrenoceptor 
antagonists, and this confirms the negative chronotropic effect of EDD (Juan-Fita et al., 
2005). The negative chronotropic effect of EDD could be the result of competitive β1 
adrenoceptor antagonism or the result of Ca2+ channel blockade (Bakheet et al., 1999; 
Somova et al., 2001). SP values with the lower doses of EDD in animals pre-treated with 
 
 
 
 
dobutamine were higher than those in non pre-treated animals. This could be due to the 
higher HR values at those doses in the pre-treated animals. In animals pre-treated with 
dobutamine, administration of the lower EDD doses led to slight increases in BP, despite 
the decreases in HR that occurred. It is important to note that although HR was decreased 
with the administration of all EDD doses in dobutamine pre-treated animals, the HR values 
were significantly higher than those obtained in animals receiving only EDD. Since 
dobutamine is known to induce increases in BP mostly via the increase in cardiac output 
produced by its β1 adrenoceptor agonist effect on the heart (a positive chronotropic and 
inotropic effect), the significant increases in BP noted here with the administration of EDD 
in animals pre-treated with dobutamine points to a synergistic effect on BP supporting the 
suggestion that EDD has a dual effect (Calvin, 1989).   
To further explore the mechanism by which EDD produced its negative chronotropic effect 
on the heart, EDD was administered to animals pre-treated with a cardio-selective Ca2+ 
channel blocker verapamil which produces decreases in HR by selective blockade of Ca2+ 
channels in cardiac myocytes (Wakabayashi et al., 1995). Decreases in HR only occurred 
with EDD doses above 1.0 mg/kg in animals pre-treated with verapamil, but verapamil pre-
treatment produced significant additive negative chronotropic effects with all EDD doses 
(see figure 4.37 and table 11). If EDD produced its negative chronotropic effect via a 
different mechanism from Ca2+ channel blockade, then additive negative chronotropic 
effects would be expected for all EDD doses in animals pre-treated with a Ca2+ channel 
blocker. The results indicate however that no significant decreases in HR occurred with the 
administration of EDD in animals pre-treated with verapamil. Calcium channel blockade 
has been identified as the mechanism of action of the cardiovascular effects of many plant 
 
 
 
 
compounds including diterpenoids (Bakheet et al., 1999; Somova et al., 2001; Consolini 
and Sarubbio 2002; Ambrosio et al., 2006; de Oliveira et al., 2006). Calcium channel 
blockade does not however only occur with the Ca2+ channels in the heart, but blockade of 
Ca2+ channels found in the contractile tissues of arteries would also produce vasodilatation 
(Fozzard, 2002). EDD on its own did not produce decreases in BP, but rather our results 
indicate that increases in BP occurred with EDD administration due to an indirect α1 
agonistic effect. Hence the vasoconstrictive and negative chronotropic effect of EDD can 
only be attributed to Ca2+ channel blockade if the Ca2+ channel effect was selective for 
myocardial Ca2+ channels only. β1 adrenoceptor agonists produce a positive chronotropic 
and inotropic effect by increasing intracellular Ca2+ in cardiac cells, and β1 adrenoreceptor 
blockade would prevent the increase of intracellular Ca2+, an effect similar to that produced 
by Ca2+ channel blockade. The implication is that the negative chronotropic effect of EDD 
is most likely due to β1 adrenoceptor antagonism.    
The results from this study are not however conclusive on the precise mechanism for the 
action of EDD and consequently, further experiments using the loose patch clamp 
technique to determine the effect of EDD on the Na+/K+ pump and isolated organ 
experiments to determine its effect on myocardial and arterial Ca2+ channels and its 
vasoconstrictor effect would be required to confirm the mechanism of action of EDD.  
 
Limitations 
The scope of this study was limited by the lack of sufficient funds and access to the 
equipment needed to carry out some of the additional experiments listed above.  
 
 
 
 
 Conclusion 
A novel diterpenoid; (13S)-9α, 13α-epoxylabda-6β(19),15(14)diol dilactone (EDD) was 
isolated from the methanol extracts of the leaves of L. leonurus using fractionation 
techniques. The chemical formula as well as the structure of the compound was determined 
using IR, NMR, MS and X-ray diffraction techniques. EDD was evaluated for its 
cardiovascular effects on the anaesthetized normotensive rat model using male Wister rats 
and was found to exhibit a dual effect on the cardiovascular system. EDD elevated BP and 
decreased HR in the animals. Using pre-treatment with standard cardio-active drugs as a 
lead, the increase in BP elicited by EDD was the result of vasoconstriction probably via the 
release of catecholamines, while its negative chronotropic effect was probably due to β1 
adrenoceptor antagonism. Further experiments are however needed to confirm these 
postulations. 
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